研究活動情報

• 2020年 日本泌尿器科学会, Top downloaded paper 2018-2019 in International Journal of Urology.


• 2019年 34th Annual Congress of European Association of Urology, Best Poster Award

  スペイン

  国際学会・会議・シンポジウム等の賞


• 2018年11月22日 第64回日本病理学会 秋期特別総会会長, 第64回日本病理学会秋期特別総会優秀ポスター賞

  第64回日本病理学会秋期特別総会でのポスター発表「The transcribed ultraconserbed region Uc.416+A is involved in sarcomatoid differentiation in renal cell carcinoma」が特に優秀であったため。


• 2018年11月03日 第70回西日本泌尿器科学会総会会長, 第70回西日本泌尿器科学会総会ヤングウロロジストリサーチコンテスト最優秀賞

  第70回 西日本泌尿器科学会総会ヤングウロロジストリサーチコンテストでの発表「KIFC1 is involved in the regulation of resistance against docetaxel and a combination of KIFC1 inhibitor and docetaxel could be a promising strategy」が特に優秀であったため。


• 2017年12月09日 日本内視鏡外科学会, Surgical Forum Award, ロボット支援腎部分切除術の術前説明における３次元模型の有用性

  亭島 淳

  日本国

  国内学会・会議・シンポジウム等の賞


• 2014年 30th Anniversary Congress of European Association of Urology, Best Poster Award

  亭島 淳

  スペイン

  国際学会・会議・シンポジウム等の賞


• 2014年 広島大学泌尿器科同門会, 仁平賞

  亭島 淳

  日本国


• 2013年 第4回日本泌尿器内視鏡学会, 第4回 学会賞

  亭島 淳

  日本国


• 2012年 第11回Hiroshima Journal of Medical Sciences優秀論文賞

  亭島 淳

  日本国


• 2012年 27th Annual Congress of European Association of Urology, Best Poster Award

  亭島 淳

  フランス共和国


• 2011年 29th World Congress of Endourology and ESWL, Olympus Award, Best of Laparoscopy and Robotics

  亭島 淳

  日本国

  国際学会・会議・シンポジウム等の賞


• 2010年 第63回広島医学会総会, 優秀賞

  亭島 淳

  日本国


• 2008年 第60回日本泌尿器科学会西日本総会, 学術奨励賞

  亭島 淳

  日本国

• HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer

  Sekino, Yohei, Quoc Thang Pham, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Shiota, Masaki, Yasui, Wataru, Teishima, Jun

  Homeobox genes function as master regulatory transcription factors during embryogenesis. HOXB5 is known to play an important role in several cancers. However, the biological role of HOXB5 in prostate cancer (PCa) is not fully elucidated. This study aimed to analyze the expression and function of HOXB5 and involvement of HOXB5 in neuroendocrine differentiation in PCa. Immunohistochemistry showed that 56 (43.8%) of 128 cases of localized PCa were positive for HOXB5. HOXB5-positive cases were associated with poor prostate-specific antigen recurrence-free survival after prostatectomy. Among 74 cases of metastatic PCa, 43 (58.1%) were positive for HOXB5. HOXB5 expression was higher in metastatic PCa than that in localized PCa. HOXB5 knockdown suppressed cell growth and invasion, but HOXB5 overexpression increased cell growth and invasion in PCa cell lines. Furthermore, HOXB5 regulated RET expression. Gene set enrichment analysis revealed that Nelson androgen response gene set was enriched in low HOXB5 expression group. RB1 knockout increased HOXB5 expression. Of note, additional p53 knockdown further increased HOXB5 expression in RB1 knockout cells. In silico analysis showed that HOXB5 expression was increased in neuroendocrine PCa (NEPC). These results suggest that HOXB5 may be a promising prognostic marker after prostatectomy and is involved in progression to NEPC.

  MDPI, 2021年08月, BIOMEDICINES, 9(8) (8), 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer

  Babasaki, Takashi, Sentani, Kazuhiro, Sekino, Yohei, Kobayashi, Go, Quoc Thang Pham, Katsuya, Narutaka, Akabane, Shintaro, Taniyama, Daiki, Hayashi, Tetsutaro, Shiota, Masaki, Oue, Naohide, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Although docetaxel (DTX) confers significant survival benefits in patients with castration-resistant prostate cancer (CRPC), resistance to DTX inevitably occurs. Therefore, clarifying the mechanisms of DTX resistance may improve survival in patients with CRPC. Claspin plays a pivotal role in DNA replication stress and damage responses and is an essential regulator for the S-phase checkpoint. CLSPN is an oncogenic gene that contributes to tumor proliferation in several human solid tumors. However, the clinical significance of claspin in prostate cancer (PCa) has not been examined. The present study aimed to elucidate the role of claspin and its relationship with DTX resistance in PCa. We immunohistochemically analyzed the expression of claspin in 89 PCa cases, of which 31 (35%) were positive for claspin. Claspin-positive cases were associated with higher Gleason score, venous invasion, and perineural invasion. Kaplan-Meier analysis showed that high claspin expression was related to poor prostate-specific antigen (PSA) relapse-free prognosis. In a public database, high CLSPN expression was associated with poor PSA relapse-free prognosis, Gleason score, T stage, lymph node metastasis, CRPC, and metastatic PCa. Claspin knockdown by siRNA decreased cell proliferation, upregulated DTX sensitivity, and suppressed the expression of Akt, Erk1/2, and CHK1 phosphorylation in DU145 and PC3 cell lines. Furthermore, claspin expression was much more upregulated in DTX-resistant DU145 (DU145-DR) than in parental DU145 cells. Claspin knockdown significantly upregulated the sensitivity to DTX in DU145-DR cells. These results suggest that claspin plays an important role in PCa tumor progression and DTX resistance.

  WILEY, 2021年08月, CANCER MEDICINE, 10(16) (16), 5574 - 5588, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Nationwide surveillance of bacterial pathogens isolated from patients with acute uncomplicated cystitis in 2018: Conducted by the Japanese Research Group for Urinary Tract Infections (JRGU)

  Wada, Koichiro, Yokoyama, Teruhiko, Uno, Satoshi, Araki, Motoo, Sadahira, Takuya, Maruyama, Yuki, Acosta, Herik, Nakajima, Hirochika, Hiyama, Yoshiki, Kunishima, Yasuharu, Togo, Yoshikazu, Nukaya, Takuhisa, Yamada, Hiroki, Shigemura, Katsumi, Ito, Shin, Tanimura, Masanobu, Kobayashi, Kanao, Kitano, Hiroyuki, Teishima, Jun, Yasuda, Mitsuru, Uehara, Shinya, Hamasuna, Ryoichi, Watanabe, Toyohiko, Nakagawa, Tohru, Hayami, Hiroshi, Miyazaki, Jun, Takahashi, Satoshi, Masumori, Naoya, Ishikawa, Kiyohito, Kiyota, Hiroshi, Fujisawa, Masato, Arakawa, Soichi, Nasu, Yasutomo, Yamamoto, Shingo

  Introduction: The aim of this study was to monitor the development of drug-resistant bacteria isolated from acute uncomplicated cystitis (AUC) and to evaluate methodology of the survey conducted by collecting only clinical data. Methods: We enrolled female patients at least 16 years of age diagnosed with AUC in 2018. Patient information including age, menopausal status, and results of bacteriological examination were collected and analyzed regardless of bacterial identification, antimicrobial susceptibility testing or extended spectrum b-lactamase (ESBL) detection method. Results: A total of 847 eligible cases were collected. Escherichia coli (E. coli) was the most frequently isolated bacterial species at about 70%, with proportions of fluoroquinolone-resistant E. coli (QREC) and ESBL-producing E. coli isolates at 15.6% and 9.5% of all E. coli isolates, respectively. The proportion of Staphylococcus saprophyticus (S. saprophyticus) was significantly higher in premenopausal women. Regarding the drug susceptibility of E. coli, isolates from Eastern Japan had significantly higher susceptibility to cefazolin, cefotiam and cefpodoxime and lower susceptibility to levofloxacin in postmenopausal women. ESBL-producing E. coli isolates had a high susceptibility to tazobactam-piperacillin, cefmetazole, carbapenems, aminoglycosides, and fosfomycin. In S. saprophyticus, the susceptibility to b-lactams including carbapenems was 40-60%. Conclusions: The proportions of QREC and ESBL-producing E. coli were increasing trends and lower susceptibility to LVFX in postmenopausal women was observed. Such surveillance, consisting of the collecting only clinical data, could be conducted easily and inexpensively. It is expected to be continuously performed as an alternative survey to conventional one collecting bacterial strains. (c) 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

  ELSEVIER, 2021年08月, JOURNAL OF INFECTION AND CHEMOTHERAPY, 27(8) (8), 1169 - 1180, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Tumor heterogeneity evaluated by computed tomography detects muscle-invasive upper tract urothelial carcinoma that is associated with inflammatory tumor microenvironment

  Goto, Keisuke, Honda, Yukiko, Ikeda, Kenichiro, Takemoto, Kenshiro, Higaki, Toru, Hayashi, Tetsutaro, Kobatake, Kohei, Nakamura, Yuko, Sekino, Yohei, Inoue, Shogo, Awai, Kazuo, Yasui, Wataru, Teishima, Jun

  To detect muscle-invasive upper tract urothelial carcinoma, we evaluated the internal texture of the tumor using texture analysis of computed tomography images in 86 cases of upper tract urothelial carcinoma. The internal texture of the tumor was evaluated as the value of computed tomography attenuation number of the unenhanced image, and the median, standard deviation, skewness and kurtosis were calculated. Each parameter was compared with clinicopathological factors, and their associations with postoperative prognosis were investigated. Immunohistochemistry was performed to investigate the histological and molecular mechanisms of the inflammatory tumor microenvironment. The histogram of computed tomography attenuation number in non-muscle invasive tumor was single-peaked, whereas muscle invasive tumor showed a multi-peaked shape. In the parameters obtained by texture analysis, standard deviation was significantly associated with pathological stage (p<0.0001), tumor grade (p=0.0053), lymphovascular invasion (p=0.0078) and concomitant carcinoma in situ (p=0.0177) along with recurrence-free (p=0.0191) and overall survival (p=0.0184). The standard deviation value correlated with the amount of stromal components (p<0.0001) and number of tumor-infiltrating macrophages (p<0.0001). In addition, higher expression of high mobility group box 1 was found in heterogeneous tumor. Tumor heterogeneity evaluated by texture analysis was associated with muscle-invasive upper tract urothelial carcinoma and represented an inflammatory tumor microenvironment and useful as the clinical assessment to differentiate muscle invasive tumor.

  NATURE RESEARCH, 2021年07月, SCIENTIFIC REPORTS, 11(1) (1), 14251 - 14251, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• The influence of reviewer's occupation on the skill assessment of urethrovesical anastomosis in robot-assisted radical prostatectomy

  Fukuoka, Kenichiro, Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Matsubara, Akio

  Introduction: In recent years, crowd-sourced assessments have been reported as a timesaving, cost-efficient, and practicable method of surgical skill evaluation. However, the differences in the assessment of surgical skills by the individual reviewers cannot be further examined in terms of characteristics of the reviewers because they are usually anonymously and randomly selected. This study aimed to reveal the effects of reviewers' occupations on their assessment of a surgeon s skill. Methods: In total, 42 urologists, 19 paramedics, 73 medical students, and 28 non-medical personnel used the Global Evaluative Assessment of Robotic Skills (GEARS) validated robotic surgery rating tool to assess the surgical skill of surgeons in nine edited video clips of complete urethrovesical anastomosis during a robot-assisted radical prostatectomy. The total GEARS scores of the four groups of reviewers were compared, and the similarities and the differences between the ratings of the urologists group and those of the other three groups were subsequently investigated. Results: The rankings of video clips in the order of GEARS scores were very similar in each group, and a strong positive correlation (R-2 values >0.8) was observed between the scores assigned by the urologists group and those assigned by the other three groups. Conclusion: Our findings indicate that the crude evaluation of robot-assisted urethrovesical anastomosis is not affected by the reviewers occupations. Non-medical personnel may be able to provide a rudimentary screening evaluation of surgical skill.

  WILEY, 2021年07月, ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 14(3) (3), 451 - 457, 国際共著していない

  [査読有り]


• TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Miyamoto, Shunsuke, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shiota, Masaki, Takeshima, Yukio, Yasui, Wataru, Matsubara, Akio

  Background: Tubulin-beta 3 encoded by the Tubulin-beta 3 (TUBB3) gene is a microtubule protein. Previous studies have shown that TUBB3 expression is upregulated in castration-resistant prostate cancer (CaP) and is involved in taxane resistance. However, the biological mechanism of TUBB3 involvement in the progression to castration-resistant CaP is not fully elucidated. This study aimed to analyze the expression and function of TUBB3 in localized and metastatic CaP. Methods: TUBB3 expression was determined using immunohistochemistry in localized and metastatic CaP. We also investigated the association between TUBB3, phosphatase and tensin homolog (PTEN), and neuroendocrine differentiation and examined the involvement of TUBB3 in new antiandrogen drugs (enzalutamide and apalutamide) resistance in metastatic CaP. Results: In 155 cases of localized CaP, immunohistochemistry showed that 5 (3.2%) of the CaP cases were positive for tubulin-beta 3. Kaplan-Meier analysis showed that high expression of tubulin-beta 3 was associated with poor prostate-specific antigen recurrence-free survival after radical prostatectomy. In 57 cases of metastatic CaP, immunohistochemistry showed that 14 (25%) cases were positive for tubulin-beta 3. Tubulin-beta 3 expression was higher in metastatic CaP than in localized CaP. High tubulin-beta 3 expression was correlated with negative PTEN expression. TUBB3 expression was increased in neuroendocrine CaP based on several public databases. PTEN knockout decreased the sensitivity to enzalutamide and apalutamide in 22Rv-1 cells. TUBB3 knockdown reversed the sensitivity to enzalutamide and apalutamide in PTEN-CRISPR 22Rv-1 cells. High expression of tubulin-beta 3 and negative expression of PTEN were significantly associated with poor overall survival in metastatic CaP treated with androgen deprivation therapy. Conclusions: These results suggest that TUBB3 may be a useful predictive biomarker for survival and play an essential role in antiandrogen resistance in CaP. (C) 2021 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, 2021年06月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 39(6) (6), 368.e1-368.e9, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy.

  Teishima J, Inoue S, Hayashi T, Matsubara A.

  2021年05月, Curr Urol, 15(2) (2), 85 - 90, 国際共著していない

  [査読有り]


• Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy

  Inoue, Shogo, Hayashi, Testutaro, Teishima, Jun, Matsubara, Akio

  Objective To evaluate the frequency of sexual intercourse and sexual activity of patients after nerve-sparing (NS) robot-assisted laparoscopic radical prostatectomy (RARP). Patients and Methods We prospectively obtained 2-years longitudinal Expanded Prostate Cancer Index Composite (EPIC) and Sexual Health Inventory for Men (SHIM) score data from 99 patients. We classified the frequency of sexual intercourse and sexual activity as 'none', 'less than once a week', 'about once a week', 'several times a week', and 'daily'. Results The percentages of patients who took part in sexual activity before and at 3, 6, 9, 12, 18, and 24 months after NS RARP were 55.6%, 27.9%, 38.8%, 42.5%, 44.4%, 41.7%, and 42.1%, respectively. The percentages of patients who took part in sexual intercourse before and at 3, 6, 9, and 12, 18, and 24 months after NS RARP were 40.4%, 9.0%, 13.3%, 16.3%, 16.7%, 22.2%, and 23.7%, respectively. Preoperative sexual status was classified into two groups: those who had sexual intercourse or those who only had sexual activity except sexual intercourse. Sexual function (SF) was investigated longitudinally using the EPIC and SHIM data between the two groups. The SHIM data showed an improvement in SF in the sexual intercourse group, but did not do so in the sexual activity except sexual intercourse group. On the other hand, SF in the EPIC data might reflect the postoperative improvement of SF in the sexual activity except sexual intercourse group. Conclusion There was a large discrepancy between the percentages of patients taking part in sexual intercourse and sexual activity; therefore, surveys of postoperative SF are recommended to include not only sexual intercourse but also sexual activity.

  WILEY, 2021年05月, BJU INTERNATIONAL, 127(5) (5), 560 - 566, 国際共著していない

  [査読有り]


• Comparison of Chief Surgeons' and Assistants' Feelings of Fatigue Between Laparoendoscopic Single-site and Conventional Laparoscopic Adrenalectomy

  Inoue, Shogo, Ikeda, Kenichiro, Goto, Keisuke, Hieda, Keisuke, Hayashi, Tetsutaro, Teishima, Jun

  Background Our objective was to compare the surgical staff's feelings of fatigue between laparoendoscopic single-site adrenalectomy (LESS-A) and conventional laparoscopic adrenalectomy (CLA) before and after surgery. Method Data were collected for surgical procedures performed between June 2011 and September 2017 (57 LESS-A and 37 CLA). Each procedure in both groups was performed by the same chief surgeon. The subjective fatigue feelings of the key members of the surgical team (chief surgeon, scopist, assistant surgeon) were assessed using the "Jikaku-sho shirabe" questionnaire, which contained questions about work-related feelings of fatigue. It consisted of 25 subjective items for 5 factors drawn from factor analysis (drowsiness, instability, uneasiness, local pain or dullness, and eyestrain). For each item, the participants were requested to estimate the intensity of their feelings using a five-point rating scale before and after surgery. Results There was no significant difference in operative time (p = 0.231) between the LESS-A and CLA procedure groups. For the chief surgeon, local pain or dullness (p = 0.603) and eyestrain (p = 0.086) were similar between the LESS-A and CLA procedures. The scopists and assistant surgeons in the LESS-A group did not suffer local pain or dullness (p = 0.793 and p = 0.240, respectively). They did, however, suffer more eyestrain than those in the CLA group (p = 0.001 and p = 0.001, respectively). Conclusion Although LESS-A is generally considered to be a technically difficult procedure, the results of this study demonstrate that the feelings of physical fatigue are roughly equivalent between LESS-A and CLA procedures.

  SPRINGER, 2021年05月, WORLD JOURNAL OF SURGERY, 45(5) (5), 1466 - 1474, 国際共著していない

  [査読有り]


• Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification

  Kohada, Yuki, Hayashi, Tetsutaro, Hsi, Ryan S., Yukihiro, Kazuma, Sentani, Kazuhiro, Goto, Keisuke, Inoue, Shogo, Ohara, Shinya, Teishima, Jun, Kajiwara, Mitsuru, Nishisaka, Takashi, Yasui, Wataru, Black, Peter C., Matsubara, Akio

  Objectives To assess the change in rates of recurrence-free survival (RFS) and progression-free survival (PFS) based on the duration of survival without recurrence or progression among patients with intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), and to examine the predictive factors for recurrence at different time points by assessing conditional RFS and PFS. Participants and Methods A cohort of 602 patients treated with transurethral resection of bladder tumour and histopathologically diagnosed with IR NMIBC was included in this retrospective study. Results The conditional RFS rate at 1, 2, 3, 4 and 5 years improved with increased duration of RFS; however, the conditional PFS rate did not improve over time. Multivariable analyses showed that recurrent tumour, multiple tumours, tumour size (>3 cm), immediate postoperative instillation of chemotherapy, and administration of BCG were independent predictive factors for recurrence at baseline. The predictive ability of these factors disappeared with increasing recurrence-free survivorship. Subclassification of these patients with IR NMIBC into three groups using clinicopathological factors (recurrent tumour, multiple tumours, tumour size) demonstrated that the high IR group (two factors) had significantly worse RFS than the intermediate (one factor,P< 0.001) and low IR groups (no factor,P= 0.005) at baseline. This subclassification stratified conditional risk of RFS also at 1, 3 and 5 years, which provides the basis for distinct surveillance protocols among patients with IR NMIBC. Conclusion Conditional survival analyses of patients with IR NMIBC demonstrate that RFS changes over time, while PFS does not change. These data support distinct surveillance protocols based on the subclassification of IR NMIBC.

  WILEY, 2021年04月, BJU INTERNATIONAL, 127(4) (4), 473 - 485, 国際共著している

  [査読有り]


• Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: A prospective multi-institutional study

  Hinata, Nobuyuki, Shiroki, Ryoichi, Tanabe, Kazunari, Eto, Masatoshi, Takenaka, Atsushi, Kawakita, Mutsushi, Hara, Isao, Hongo, Fumiya, Ibuki, Naokazu, Nasu, Yasutomo, Teishima, Jun, Kawai, Noriyasu, Kawauchi, Akihiro, Kondo, Tsunenori, Kawamorita, Naoki, Oyama, Chikara, Horie, Shigeo, Shimbo, Masaki, Kato, Masashi, Kanayama, Hiroomi, Koito, Yuya, Fujisawa, Masato

  Objective To investigate whether robot-assisted partial nephrectomy compared with laparoscopic partial nephrectomy is effective for renal hilar tumor removal. Methods This was a prospective, multicenter, single-arm, open-label trial with a 2-year enrollment period. A total of 22 academic hospitals in Japan participated in the present study. Comparison with historical control values from reported studies of laparoscopic partial nephrectomy was carried out. The warm ischemia time and positive surgical margin rate were set as primary perioperative and oncological outcomes. In the historical control group, these were 27.7 min and 13%, respectively. Results The analysis population included 105 participants. The mean warm ischemia time was 20.2 (95% confidence interval 16.7-21.8; P vs 27.7). Two of 103 participants (1.9%) had a positive surgical margin (95% confidence interval 0.5-6.8%). Both results satisfy the prespecified decision criteria for the superiority of robot-assisted partial nephrectomy over the historical control of laparoscopic partial nephrectomy. Resected weight and preoperative estimated glomerular filtration rate were predictive factors of functional loss of the partially nephrectomized kidney after robot-assisted partial nephrectomy. Conclusion Robot-assisted partial nephrectomy for clinical T1 renal hilar tumors results in shorter warm ischemia time than and comparable positive surgical margin rate to those reported for laparoscopic partial nephrectomy.

  WILEY, 2021年04月, INTERNATIONAL JOURNAL OF UROLOGY, 28(4) (4), 382 - 389, 国際共著していない

  [査読有り]


• Postoperative around-the-clock administration of intravenous acetaminophen for pain control following robot-assisted radical prostatectomy

  Inoue, Shogo, Miyoshi, Hirotsugu, Hieda, Keisuke, Hayashi, Tetsutaro, Tsutsumi, Yasuo M., Teishima, Jun

  The objective of this study was to examine the impact of around-the-clock (ATC) administration of intravenous (IV) acetaminophen following robot-assisted radical prostatectomy (RARP). Intravenous infusion of acetaminophen was started on the day of the operation at 1000 mg/dose every 6 h, and the infusion was continued on a fixed schedule until postoperative day 2 a.m. In a retrospective observational study, we compared 127 patients who were administered IV acetaminophen on a fixed schedule (ATC group) with 485 patients who were administered analgesic drugs only as needed (PRN group). We investigated postoperative pain intensity and additional analgesic consumption on postoperative day 0, 1, 2, 3, and 5 between the two groups. Postoperative pain scores were significantly lower in the ATC group than in the PRN group at 1 and 2 days, and this period matched the duration of ATC administration of IV acetaminophen. Postoperative frequency of rescue analgesia was significantly lower in the ATC group than in the PRN group at postoperative 0, 1, and 2 days. ATC administration of IV acetaminophen has the potential to be a very versatile and valuable additional dose to achieve appropriate postoperative analgesia in patients with RARP.

  NATURE RESEARCH, 2021年03月, SCIENTIFIC REPORTS, 11(1) (1), 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma

  Sekino, Yohei, Han, Xiangrui, Kobayashi, Go, Babasaki, Takashi, Miyamoto, Shunsuke, Kobatake, Kohei, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Introduction: BUB1 mitotic checkpoint serine/threonine kinase B encoded by BUB1B gene is a member of the spindle assembly checkpoint family. Several reports have demonstrated that overexpression of BUB1B is associated with cancer progression and prognosis. Objective: This study aims to clarify the expression and function of BUB1B in renal cell carcinoma (RCC). Methods: The expression of BUB1B was determined using immunohistochemistry and bioinformatics analysis in RCC. The effects of BUB1B knockdown on cell growth and invasion were evaluated. We analyzed the interaction between BUB1B, cancer stem cell markers, p53, and PD-L1 in RCC. Results: In 121 cases of RCC, immunohistochemistry showed that 30 (25%) of the RCC cases were positive for BUB1B. High BUB1B expression was significantly correlated with high nuclear grade, T stage, and M stage. A Kaplan-Meier analysis showed that the high expression of BUB1B was associated with poor overall survival after nephrectomy. High BUB1B expression was associated with CD44, p53, and PD-L1 in RCC. Knockdown of BUB1B suppressed cell growth and invasion in RCC cell lines. Knockdown of BUB1B also suppressed the expression of CD44 and increased the expression of phospho-p53 (Ser15). In silico analysis showed that BUB1B was associated with inflamed CD8+, exhausted T-cell signature, IFN-gamma signature, and the response to nivolumab. Conclusion: These results suggest that BUB1B plays an oncogenic role and may be a promising predictive biomarker for survival in RCC.

  KARGER, 2021年03月, ONCOLOGY, 99(4) (4), 240 - 250, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection

  Kitano, Hiroyuki, Shigemoto, Norifumi, Koba, Yumiko, Hara, Toshinori, Seiya, Kashiyama, Omori, Keitaro, Shigemura, Katsumi, Teishima, Jun, Fujisawa, Masato, Matsubara, Akio, Ohge, Hiroki

  Purpose Staphylococcus aureus is a relatively uncommon causative agent of urinary tract infection (UTI). However, the clinical features of S. aureus-related UTI are unclear. Thus, we aimed to clarify how patients with S. aureus bacteriuria develop UTI and determine the features and clinical risk factors of symptomatic S. aureus-related UTI. Methods We performed a retrospective study of patients at the Hiroshima University Hospital for whom S. aureus had been isolated from urine culture from January 2010 to December 2017. The characteristics (age, sex, body mass index, indwelling catheterization, renal stones, hydronephrosis, anticancer drug use, diabetes mellitus, steroid use, serum albumin, antibiotic use in the past 1 month, estimated glomerular filtration rate, benign prostate hyperplasia, and neurogenic bladder) of patients with UTI and those without UTI were compared, and the risk factors for S. aureus-related UTI were identified by multiple logistic regression model. Results A total of 286 patients with S. aureus bacteriuria were analyzed; 33 patients developed UTI. The causative pathogens were methicillin-sensitive S. aureus and methicillin-resistant S. aureus (MRSA) in 14 and 19 patients, respectively, who developed UTI. This study demonstrated that indwelling catheterization, hydronephrosis, and renal stones are significantly associated with S. aureus-related UTI (p = 0.01, odds ratio = 3.1; and p < 0.01, odds ratio = 7.0; and p = 0.02, odds ratio = 1.2; respectively) and hypoalbuminemia in MRSA-related UTI (p < 0.01). Conclusion Paying attention to risk factors, specifically indwelling catheterization, renal stones, and hydronephrosis, will be an effective strategy for prevention of S. aureus-related UTI with persistent staphylococcal bacteriuria.

  SPRINGER, 2021年02月, WORLD JOURNAL OF UROLOGY, 39(2) (2), 511 - 516, 国際共著していない

  [査読有り]


• Impact of postoperative acute kidney injury on predicting the upstaging of chronic kidney disease after robot-assisted partial nephrectomy

  Teishima, Jun, Inoue, Shogo, Miyamoto, Shunsuke, Fukuoka, Kenichiro, Sekino, Yohei, Kitano, Hiroyuki, Hieda, Keisuke, Hayashi, Tetsutaro, Matsubara, Akio

  Introduction: The aim of our study was to assess the impact of acute kidney injury (AKI) on postoperative upstaging of chronic kidney disease (CKD) after robot-assisted partial nephrectomy (RAPN). Methods: This study consisted of 110 patients who had undergone RAPN and were followed up for at least 6 months after surgery. Patients were classified as AKI or non-AKI based on their serum creatinine level and estimated glomerular filtration rate within 7 days after surgery. Patient characteristics, outcome of RAPN and estimated glomerular filtration rate, and CKD upstage 6 months after surgery were compared between the AKI and non-AKI groups. Results: A total of 26 patients (23.6%) experienced AKI after surgery. RENAL (radius, exophytic/endophitic properties, nearness of the tumor to the collecting system or sinus, anterior/posterior, location relative to the polar lines) nephrometry scores were >= 7 for 22 (84.6%) in the AKI group and 39 (46.4%) in the non-AKI group (P= .0006). A significantly smaller proportion of patients in the AKI group than in the non-AKI group recovered 90% of baseline function (38.5% vs 81.0%, P< .0001). CKD upstaging occurred in a total of 27 patients 24.5%) and in a significantly larger proportion of patients in the AKI group than in the non-AKI group (42.3% vs 19.0%, P = .0160). There was no significant difference in characteristics and perioperative outcomes between the patients with and without CKD, except for in those experiencing AKI. Conclusion: After RAPN, AKI can be associated with CKD upstaging.

  WILEY, 2021年01月, ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 14(1) (1), 50 - 56, 国際共著していない

  [査読有り]


• Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma

  Sazuka, Tomokazu, Sakamoto, Shinichi, Imamura, Yusuke, Nakamura, Kazuyoshi, Yamamoto, Satoshi, Arai, Takayuki, Takeuchi, Nobuyoshi, Komiya, Akira, Teishima, Jun, Ichikawa, Tomohiko

  Objectives To evaluate the relationship between residual urine volume, pyuria and bladder carcinoma recurrence. Methods The clinical data of 305 patients who had post-void residual urine volume measured and preoperative pyuria were retrospectively collected. The patients were classified into three risk groups based on the presence of residual urine and pyuria: good (negative residual urine and pyuria), intermediate (positive residual urine or pyuria) and poor (positive residual urine and pyuria). Predictive factors for intravesical recurrence-free survival were statistically analyzed using Cox proportional hazard models and Kaplan-Meier methods. The propensity score matching method was used to adjust the patients' backgrounds. Results The median follow-up period for all patients was 44 months. The presence of residual urine (P = 0.0164) and pyuria (P = 0.0233) were two independent prognostic factors for recurrence. After patients were classified into risk groups, the poor-risk group showed significantly shorter recurrence-free survival compared with that of the good- (P = 0.0002) and intermediate-risk groups (P = 0.0090). Even after matching, the presence of residual urine was related to short recurrence-free survival in male patients (P = 0.0012). When stratified by European Organization for Research and Treatment of Cancer risk groups, the presence of pyuria was related to short recurrence-free survival, especially for intermediate-risk patients without bacillus Calmette-Guerin treatment. Conclusions Post-void residual urine and preoperative pyuria are two risks for recurrence-free survival in non-muscle-invasive bladder cancer.

  WILEY, 2020年11月, INTERNATIONAL JOURNAL OF UROLOGY, 27(11) (11), 1024 - 1030, 国際共著していない

  [査読有り]


• Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors

  Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Mita, Koji, Hasegawa, Yasuhisa, Kato, Masao, Kajiwara, Mitsuru, Shigeta, Masanobu, Maruyama, Satoshi, Moriyama, Hiroyuki, Fujiwara, Seiji, Matsubara, Akio

  Introduction: International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the most representative risk model for patients with metastatic renal cell carcinoma (mRCC). However, the intermediate-risk group of IMDC criteria is thought to include patients with different prognoses because many of the patients are classified into the intermediate-risk group. In this study, we investigated the impact of systemic immune-inflammation index (SII), which is calculated based on neutrophil count, platelet count, and lymphocyte count, on predicting the prognosis in patients with mRCC, and its usefulness for re-classification of patients with a more sophisticated risk model. Methods: From January 2008 to January 2018, 179 mRCC patients with a pretreatment and SII were retrospectively investigated. All patients were classified into either a high-SII group or a low-SII group based on the cutoff value of a SII at 730, as reported in previous studies; the overall survival (OS) rates in each group were compared. Results: The median age was 65 years old. Males and females comprised 145 and 34 cases, respectively. The categories of favorable-, intermediate-, and poor-risk groups in the IMDC model were assessed in 39, 102, and 38 cases, respectively. The median observation period was 24 months. The low-SII and high-SII groups consisted of 73 and 106 cases, respectively. The 50% OS in the high-SI! group was 21.4 months, which was significantly worse than that in the low-SII group (49.7 months; p<0.0001). Multivariate analysis showed that a high SII was an independent predictive factor for a worse OS. Next, we constructed a modified IMDC risk model that included the 511 instead of a neutrophil count and a platelet count. By using this modified IMDC model, all cases were re-classified into four groups of 33, 52, 81, and 13 cases with 50% OS of 88.8, 45.9, 29.4, and 4.8 months, respectively. Conclusions: The SII is useful for establishing a more sophisticated prognostic model that can stratify mRCC patients into four groups with different prognoses.

  CANADIAN UROLOGICAL ASSOCIATION, 2020年11月, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 14(11) (11), E582 - E587, 国際共著していない

  [査読有り]


• TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Miyamoto, Shunsuke, Kitano, Hiroyuki, Kobayashi, Go, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Background:beta III-Tubulin, encoded by theTUBB3gene, is a microtubule protein. Several studies have shown that overexpression of TUBB3 is linked to poor prognosis and is involved in taxane resistance in some cancers.Objective:The aim of this study was to analyze the expression and function of TUBB3 in clear cell renal cell carcinoma (ccRCC).Methods:The expression of TUBB3 was determined using immuno-histochemistry in ccRCC specimens. The effects of TUBB3 knockdown on cell growth and invasion were evaluated in RCC cell lines. We analyzed the interaction between TUBB3, p53, cancer stem cell markers, and PD-L1.Results:In 137 cases of ccRCC, immunohistochemistry showed that 28 (20%) of the ccRCC cases were positive for TUBB3. High TUBB3 expression was significantly correlated with high nuclear grade, high T stage, and N stage. A Kaplan-Meier analysis showed that high expression of TUBB3 was associated with poor overall survival after nephrectomy. In silico analysis also showed that high TUBB3 expression was correlated with overall survival. Knockdown of TUBB3 suppressed cell growth and invasion in 786-O and Caki-1 cells. High TUBB3 expression was associated with CD44, CD133, PD-L1, and p53 in ccRCC. We generated p53 knockout cells using the CRISPR-Cas9 system. Western blotting revealed that p53 knockout upregulated the expression of TUBB3.Conclusion:These results suggest that TUBB3 may play an oncogenic role and could be a potential therapeutic target in ccRCC.

  KARGER, 2020年10月, ONCOLOGY, 98(10) (10), 689 - 698, 国際共著していない

  [査読有り]


• Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer

  Sekino, Yohei, Han, Xiangrui, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shiota, Masaki, Takeshima, Yukio, Yasui, Wataru, Matsubara, Akio

  Introduction: Microtubule-associated protein tau (MAPT), facilitates tubulin assembly and microtubule stabilization. Several studies have shown that overexpression of MAPT is linked to poor prognosis and is involved in taxane resistance in cancer. This study aimed to assess the expression and function of MAPT in prostate cancer (CaP). Methods: The expression of MAPT was determined using immunohistochemistry in CaP. We analyzed the interaction between MAPT, Phosphatase and Tensin Homolog (PTEN), and androgen receptor and investigated the role of MAPT in bicalutamide resistance. Results: Immunohistochemistry in 155 CaP cases showed that 15% of them were positive for MAPT. High MAPT expression was significantly orrelated with high Gleason score and high T stage. Kaplan-Meier analysis showed that the high MAPT expression was significantly associated with poor prostate-specific antigen recurrence survival after radical prostatectomy. There was an inverse correlation between MAPT and PTEN. In the CaP cell lines, knockout of PTEN increased the expression of MAPT, whereas knockdown of MAPT suppressed the expression of androgen receptor and increased the sensitivity to bicalutamide. Furthermore, immunohistochemical staining of MAPT showed that high MAPT expression was significantly associated with poor overall survival in 74 CaP patients who were treated with androgen deprivation therapy. Conclusion: These results suggest that MAPT may be a promising predictive biomarker for survival and play an essential role in bicalutamide resistance in CaP. (C) 2020 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, 2020年10月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(10) (10), 795.e1-795.e8, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Primary adenocarcinoma of the rete testis with elevated serum CA19-9 antigen levels

  Kitano, Hiroyuki, Sentani, Kazuhiro, Goto, Keisuke, Sekino, Yohei, Yamanaka, Ryoken, Nagasaka, Keiji, Shigematsu, Yoshinori, Kobayashi, Kanao, Hayashi, Tetsutaro, Yasui, Wataru, Teishima, Jun

  Primary adenocarcinoma of the rete testis is an extremely rare tumor with a poor prognosis. Herein, we report a case of primary adenocarcinoma of the rete testis accompanied by elevated serum carbohydrate antigen 19-9 (CA19-9) antigen levels in a 44-year-old man who presented with left scrotal swelling. Para-aortic lymph node swelling was observed on the computed tomography scan. Germ cell tumor markers were within the normal range, but serum CA19-9 antigen levels were high. Radical orchiectomy was performed, and histological examination revealed primary adenocarcinoma of the rete testis with no evidence of other primary carcinomas. The patient underwent three lines of chemotherapy, although no reports suggest the use of gemcitabine and oxaliplatin (GEMOX) in a patient with adenocarcinoma of the rete testis. Unfortunately, he developed metastasis at multiple sites and passed away due to adenocarcinoma 13 months after undergoing orchiectomy. Some reports suggest that CA19-9 antigen levels are elevated in patients with adenocarcinoma of the rete testis, although it has not been clarified whether elevated CA19-9 antigen levels reflect the progression of adenocarcinoma of the rete testis. In this case, as CA19-9 antigen levels increased with progression, CA19-9 might be a marker for primary adenocarcinoma of the rete testis. GEMOX chemotherapy as a line of treatment in primary adenocarcinoma of the rete testis has not been reported. Therefore, further studies must evaluate the efficacy of the aforementioned chemotherapy regimen.

  SPRINGER INTERNATIONAL PUBLISHING AG, 2020年10月, INTERNATIONAL CANCER CONFERENCE JOURNAL, 9(4) (4), 240 - 243, 国際共著していない

  [査読有り]


• Impact of Adrenalectomy on Cortisol-Producing Adenoma: Longitudinal Evaluation of Health-Related Quality of Life following Laparoscopic Adrenalectomy

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Introduction:There is increasing interest in evaluating the quality of life of patients with cortisol-producing adrenocortical adenoma (CPA). Our objective was to assess patient-reported health-related quality of life (HRQOL) in patients with CPA compared to non-CPA.Methods:Between January 2012 and September 2015, a total of 24 and 62 patients who had laparoscopic adrenalectomy with CPA and non-CPA, respectively, were included in the study. General HRQOL was evaluated on Short Form 8 (SF-8) questionnaire. The SF-8 questionnaire was administered at preoperative baseline and at 3, 6, 9, 12, 18, and 24 months after adrenalectomy. The impact of changing 2 measures of the summary score on the physical component summary (PCS) and mental component summary (MCS) score of SF-8 was evaluated in prospective and longitudinal studies.Results:The baseline PCS score was significantly lower in the CPA than in the non-CPA group (43.6 vs. 49.0;p= 0.0075). Thereafter, the PCS score was significantly lower in the CPA group at 3, 6, 9, and 12 months postoperatively. The PCS score increased in the CPA group with no significant difference between both groups at 18 months (48.1 vs. 50.2;p= 0.1202) and 24 months (48.0 vs. 50.8;p= 0.3625) postoperatively. However, the baseline MCS score was not significantly different between the CPA and non-CPA group. The MCS score in both groups gradually increased with no significant differences between the groups at any time points after surgery. The PCS score was not significantly improved at all postoperative points than the baseline score in the CPA and non-CPA group. The MCS score was significantly improved than the baseline score from 6 months postoperatively only in the CPA group.Conclusion:Our research suggests that laparoscopic adrenalectomy may contribute to improving the physical and mental function in HRQOL.

  KARGER, 2020年09月, UROLOGIA INTERNATIONALIS, 104(9-10) (9-10), 789 - 796, 国際共著していない

  [査読有り]


• The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy

  Takemoto, Kenshiro, Teishima, Jun, Kohada, Yuki, Ikeda, Kenichiro, Nagamatsu, Hirotaka, Goriki, Akihiro, Inoue, Shogo, Hayashi, Tetsutaro, Kajiwara, Mitsuru, Matsubara, Akio

  Background/Aim: Bladder cancer with histological variant (HV) has different morphological features from usual urothelial carcinoma (UC). The aim of this study was to evaluate the oncological outcomes of HV in patients with bladder cancer. Patients and Methods: We retrospectively evaluated data from 102 patients with UC of the bladder treated with radical cystectomy between 1998 and 2017. Pathological findings including HV were assigned by one dedicated pathologist. Recurrence-free survival (RFS) and cancer-specific survival (CSS) and overall survival (OS) were estimated by Cox regression models. Results: In total, 26 patients (25.5%) had HV, and the most common variant was squamous differentiation, followed by glandular differentiation and a mixed variant consisted of squamous and glandular differentiation. The presence of HV was associated with RFS and CSS (p=0.018, p=0.036, respectively). Conclusion: HV has more aggressive tumor biological features compared to those with pure UC. The presence of HV was associated with poor survival.

  INT INST ANTICANCER RESEARCH, 2020年08月, ANTICANCER RESEARCH, 40(8) (8), 4787 - 4793, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC

  Tomita, Yoshihiko, Naito, Sei, Sassa, Naoto, Takahashi, Atsushi, Kondo, Tsunenori, Koie, Takuya, Obara, Wataru, Kobayashi, Yasuyuki, Teishima, Jun, Takahashi, Masayuki, Matsuyama, Hideyasu, Ueda, Takeshi, Yamaguchi, Kenya, Kishida, Takeshi, Shiroki, Ryoichi, Saika, Takashi, Shinohara, Nobuo, Oya, Mototsugu, Kanayama, Hiro-omi

  The aim of the present randomized controlled study was to compare the efficacy of sunitinib and sorafenib as first-line treatment of patients with metastatic clear cell renal cell carcinoma with favorable or intermediate Memorial Sloan Kettering Cancer Center risk. The median first progression-free survival was 8.7 and 7.0 months in the sunitinib and sorafenib groups, respectively (hazard ratio, 0.67; 95% confidence interval, 0.42-1.08). Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment of metastatic clear cell renal cell carcinoma (mCC-RCC) with favorable or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) risk. Patients and Methods: Treatment-naive patients with mCC-RCC were randomized to receive open-label sunitinib followed by sorafenib (SU/SO) or sorafenib followed by sunitinib (SO/SU). The primary endpoint was firstline progression-free survival (PFS). The secondary endpoints were total PFS and overall survival (OS). Results: Of the 124 patients enrolled at 39 institutions from February 2010 to July 2012, 120 were evaluated. The median first-line PFS duration was 8.7 and 7.0 months in the SU/SO and SO/SU groups, respectively (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.42-1.08). The total PFS and OS were not significantly different between the SU/SO and SO/SU groups (27.8 and 22.6 months; HR, 0.73; 95% CI, 0.428-1.246; and 38.4 and 30.9 months; HR, 0.934; 95% CI, 0.588-1.485, respectively). The subgroup analysis revealed that the total PFS with SU/SO was superior to the total PFS with SO/SU in the patients with favorable MSKCC risk and those with < 5 metastatic sites). SO/SU was superior to SU/SO for patients without previous nephrectomy. Conclusions: No statistically significant differences were found in first-line PFS, total PFS, or OS between the 2 treatment arms. (C) 2020 The Authors. Published by Elsevier Inc.

  CIG MEDIA GROUP, LP, 2020年08月, CLINICAL GENITOURINARY CANCER, 18(4) (4), E374 - E385, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Renal metastasis from primary hepatocellular carcinoma: a case report

  Yamanaka, Ryoken, Sekino, Yohei, Babasaki, Takashi, Kitano, Hiroyuki, Ikeda, Kenichiro, Goto, Keisuke, Hieda, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Aikata, Hiroshi, Chayama, Kazuaki, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  We report a rare case of renal metastasis from primary hepatocellular carcinoma (HCC). A mass in the right kidney of a 71-year-old man was detected by follow-up computed tomography (CT) for HCC. He was diagnosed as having primary HCC 18 years ago and had undergone partial hepatectomy, transarterial chemoembolization, and pulmonary segmentectomy for primary HCC and its metastasis over 10 years. Eight years after this, follow-up CT revealed a right kidney mass, and laboratory testing showed an elevated level of protein induced by vitamin K absence II (PIVKA-II). We performed laparoscopic radical nephrectomy for the right kidney mass. Histopathology revealed renal metastasis from primary HCC. To date, only a small number of cases of renal metastasis from HCC have been reported.

  SPRINGER INTERNATIONAL PUBLISHING AG, 2020年07月, INTERNATIONAL CANCER CONFERENCE JOURNAL, 9(3) (3), 141 - 145, 国際共著していない

  [査読有り]


• Microtubule-associated protein tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma

  Han, Xiangrui, Sekino, Yohei, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayash, Tetsutaro, Teishima, Jun, Sakamoto, Naoya, Sentani, Kazuhiro, Oue, Naohide, Yasui, Wataru, Matsubara, Akio

  Introduction: Microtubule-associated protein tau (MAPT) overexpression has been linked to poor prognosis in several cancers. MAPT-AS1 is a long noncoding RNA existing at the antisense strand of the MAPT promoter region. The clinical significance of MAPT and MAPT-AS-1 in clear cell renal cell carcinoma (ccRCC) is unknown. This study aimed to assess the expression and function of MAPT and MAPT-AS1 in ccRCC. Methods: The expression of MAPT was determined using immunohistochemistry in ccRCC. The effects of MAPT knockdown on cell growth and invasion were evaluated and the interaction between MAPT and microtubule-associated protein tau antisense (MAPT-AS1) were analyzed. The expression of MAPT-AS1 was determined using quantitative reverse transcription polymerase chain reaction in ccRCC tissues. We investigated the effect of MAPT-AS1 knockdown on cell growth and invasion. We analyzed the regulation of MAPT and MAPT-AS1. Results: Immunohistochemistry in 135 ccRCC cases showed that 61% of the cases were positive for MAPT. Kaplan-Meier analysis showed that the low expression of MAPT was associated with poor overall survival after nephrectomy. Knockdown of MAPT enhanced cell growth and invasion. quantitative reverse transcription polymerase chain reaction revealed a positive correlation between MAPT and MAPT-AS1. The expression of MAPT-AS1 was higher in ccRCC tissue than in nonneoplastic kidney tissue. Kaplan-Meier analysis showed that the low expression of MAPT-AS1 was associated with poor overall survival after nephrectomy by in silico analysis. MAPT-AS1 knockdown promoted cell growth and invasion activity. P53 knockout suppressed the expression of MAPT and MAPT-AS1. Conclusion: These results suggest that MAPT and MAPT-AS1 may be promising predictive biomarkers for survival and play a tumor-suppressive role in ccRCC. (C) 2020 Elsevier Inc. All rights reserved.

  ELSEVIER SCIENCE INC, 2020年06月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 38(6) (6), 国際共著していない

  [査読有り]


• Impact of radiological morphology of clinical T1 renal cell carcinoma on the prediction of upstaging to pathological T3.

  Teishima J, Hayashi T, Kitano H, Sadahide K, Sekino Y, Goto K, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.

  Objectives: Previous studies have reported that cases with clinical T1 renal cell cancer upstaging to pathological T3 are a risk factor to predicting postoperative recurrence after partial nephrectomy. The aim of our study was to investigate the impact of the radiological morphology of the enhanced CT scan of clinical T1 renal cell cancer on predicting upstaging to pathological T3. Methods: Three hundred sixty-seven cases with clinical T1 renal cell cancer diagnosed from enhanced CT scans were enrolled in this study. Based on the findings from the enhanced CT scan, the cases were classified into 'round', the margins of which were smooth and round; 'lobular', one or more findings of smooth dent and no spiky dent were identified on the margin of the tumor; and 'irregular', one or more spiky dent were identified on the margin of the tumor. The association of postoperative upstaging with these radiological morphology and other clinical characteristics of each case was analyzed. Results: Eighteen cases (4.9%) pathologically upstaged to T3a. Two round case (0.7%), 3 lobular cases (10.0%) and 13 irregular cases (22.0%) pathologically upstaged (P < 0.001, round + lobular versus irregular). Four of 17 cases (23.5%) with hilar tumors pathologically upstaged, while 14 of 350 cases (4%) with tumors pathologically upstaged in other sites (P < 0.001). Multivariate analysis revealed that irregular case was an independent factor in predicting upstaging to pathological T3a (P < 0.001). Conclusions: Evaluation of the radiological morphology of clinical T1 renal cell cancer based on enhanced CT scans is useful for predicting pathological upstaging.

  OXFORD UNIV PRESS, 2020年04月, Jpn J Clin Oncol., 50(4) (4), 473 - 478, 国際共著していない

  [査読有り]


• PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma

  Sekino, Yohei, Hagura, Takeshi, Han, Xiangrui, Babasaki, Takashi, Goto, Keisuke, Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Shigeta, Masanobu, Taniyama, Daiki, Kuraoka, Kazuya, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  Background/Aim: Targeted receptor tyrosine kinase inhibitor (TKI) is a standard treatment in advanced renal cell carcinoma (RCC). However, the role of PTEN in TKI resistance remains poorly understood. We aimed to determine the functional role of PTEN knockout and analyse the predictive significance of PTEN expression for TKI treatment in RCC. Materials and Methods: We developed PTEN knockout cells in RCC cell lines using the CRISPR-Cas9 system and analysed the effect of PTEN knockout on spheroid formation and resistance to sunitinib and sorafenib. Results: PTEN knockout promoted spheroid formation and decreased sunitinib/sorafenib sensitivity in RCC cell lines. PTEN immunohistochemistry in 74 metastatic RCCs treated with sunitinib and sorafenib revealed negative PTEN expression in 23% of samples. Kaplan-Meier analysis showed a significant association of negative PTEN expression with poor progression-free survival in metastatic RCC treated with sunitinib and sorafenib (p=0.024) or sunitinib alone (p=0.009). Conclusion: PTEN may be a biomarker and therapeutic target in patients with metastatic RCC.

  INT INST ANTICANCER RESEARCH, 2020年04月, ANTICANCER RESEARCH, 40(4) (4), 1943 - 1951, 国際共著していない

  [査読有り]


• Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy.

  Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S.

  The present study investigated the outcomes of targeted therapy for elderly patients with metastatic renal cell carcinoma (mRCC). A total of 277 patients with mRCC who were treated with tyrosine kinase inhibitor as a first-line therapy from January 2008 to May 2018 were retrospectively investigated by reviewing clinicopathological data. Patients 75 years or older were classified into the older-aged group (n=55) while all others were classified into the younger-aged group (n=222). The preoperative clinicopathological characteristics and the overall survival (OS) rate for these two groups were subsequently compared. The median age in the older- and younger-aged groups was 78 and 63 years (P<0.0001), respectively. A total of 7, 42 and 6 cases in the older-aged group and 46, 118 and 58 cases in the younger-aged group were classified into favorable, intermediate, and poor risk groups, respectively. The rate of patients with cardiovascular diseases (29.1%) and malignant diseases other than RCC (20.0%) was significantly higher in the older-aged group compared with the younger-aged group (6.8%; P<0.0001 and 7.2%; P=0.0042, respectively). There was a significant improvement in the OS rate for patients beginning targeted therapy after 2011 compared with those starting therapy prior to 2010. The 50% OS rate in patients starting targeted therapy before 2010 and after 2011 was, respectively, 17.1 and 38.6 months for the older-aged group (P=0.0066), while there was no significant difference for the younger-aged group (P=0.1441; 50% OS; 35.9 vs. 30.5 months). The results of the present study indicated that the prognosis for older patients has improved since the introduction of targeted therapy.

  SPANDIDOS PUBL LTD, 2020年03月, Mol Clin Oncol., 12(6) (6), 557 - 564, 国際共著していない

  [査読有り]


• Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma

  Kobayashi, Go, Sentani, Kazuhiro, Babasaki, Takashi, Sekino, Yohei, Shigematsu, Yoshinori, Hayashi, Tetsutaro, Oue, Naohide, Teishima, Jun, Matsubara, Akio, Sasaki, Naomi, Yasui, Wataru

  Renal cell carcinoma (RCC) is one of the most common human cancers. We previously reported that claspin is a key regulator in the progression of gastric cancer, and it likely plays an important role in cancer stem cells of gastric cancer. However, the significance of claspin in RCC has not been examined. First, we analyzed the expression and distribution of claspin in 95 RCC cases by immunohistochemistry. In the nonneoplastic kidney, the staining of claspin was either weak or absent, whereas RCC tissue showed nuclear staining. In total, claspin expression was detected in 45 (47%) of 95 RCC cases. The claspin staining appeared relatively stronger in high nuclear grade RCC than in low nuclear grade RCC. Claspin-positive RCC cases were associated with higher T grade, tumor stage, nuclear grade, vein invasion, and poorer prognosis. CLSPN siRNA treatment decreased RCC cell proliferation. The levels of phosphorylated Erk and Akt were lower in CLSPN siRNA-transfected RCC cells than in control cells. In addition, claspin was coexpressed with CD44, epidermal growth factor receptor, p53, and programmed death ligand-1. These results suggest that claspin plays an important role in tumor progression in RCC and might be a prognostic marker and novel therapeutic target molecule.

  WILEY, 2020年03月, CANCER SCIENCE, 111(3) (3), 1020 - 1027, 国際共著していない

  [査読有り]


• Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy

  Fujii, Shinsuke, Hayashi, Tetsutaro, Honda, Yukiko, Terada, Hiroaki, Akita, Ryuji, Kitamura, Naoyuki, Ueda, Eikoh, Han, Xiangrui, Ueno, Takeshi, Miyamoto, Shunsuke, Kitano, Hiroyuki, Inoue, Shogo, Teishima, Jun, Abdi, Hamidreza, Awai, Kazuo, Takeshima, Yukio, Sentani, Kazuhiro, Yasui, Wataru, Matsubara, Akio

  Objective To assess the clinical benefits of magnetic resonance imaging/transrectal ultrasound fusion-targeted biopsy for biopsy-naive Japanese men. Methods Between February 2017 and August 2018, 131 biopsy-naive men who underwent targeted biopsy together with 10-core systematic biopsy at Hiroshima University Hospital were retrospectively investigated. Multiparametric magnetic resonance imaging findings were reported based on Prostate Imaging Reporting and Data System version 2. Results The overall cancer detection rates per patient were 69.5% in systematic biopsy + targeted biopsy cores, 61.1% in systematic biopsy cores and 61.1% in targeted biopsy cores. The detection rates for clinically significant prostate cancer were 43.5% in targeted biopsy cores and 35.9% in systematic biopsy cores (P = 0.04), whereas the detection rates for clinically insignificant prostate cancer were 17.6% and 25.2% respectively (P = 0.04). Lesions in the peripheral zone were diagnosed more with clinically significant prostate cancer (54.8% vs 20.7%, P < 0.001) and International Society of Urological Pathology grade (3.2 vs 2.7, P = 0.02) than that in the inner gland. Just 4.2% (3/71) of Prostate Imaging Reporting and Data System category 2 and 3 lesions in the middle or base of the inner gland were found to have clinically significant prostate cancer. The cancer detection rate per core was 42.3% in targeted biopsy cores, whereas it was 17.9% in systematic biopsy cores (P < 0.001). Conclusions Targeted biopsy is able to improve the diagnostic accuracy of biopsy in detection of clinically significant prostate cancer by reducing the number of clinically insignificant prostate cancer detections compared with 10-core systematic biopsy in biopsy-naive Japanese men. In addition, the present findings suggest that patients with Prostate Imaging Reporting and Data System category 2 or 3 lesions at the middle or base of the inner gland might avoid biopsies.

  WILEY, 2020年02月, INTERNATIONAL JOURNAL OF UROLOGY, 27(2) (2), 140 - 146, 国際共著している

  [査読有り]


• Comparative analysis of robot-assisted, laparoscopic, and open radical prostatectomy regarding lower urinary tract symptoms: A longitudinal study

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Purpose: This study aims to assess lower urinary tract symptoms (LUTS) after radical prostatectomy (RP) and compare longitudinally the short-time LUTS changes of three techniques: robot-assisted RP (RARP), laparoscopic RP (LRP), and open RP (ORP). Materials and Methods: We reviewed prospectively the collected longitudinal data on the International Prostate Symptom Score (IPSS) from patients who performed RP for localized prostate cancer. One-year longitudinal data (preoperatively and at postoperative 3, 6, and 12 months) on IPSS were available for 322 patients. The number of patients was 231 for RARP, 42 for LRP, and 49 for ORP. LUTS was assessed on the basis of the IPSS and the IPSS quality of life (QOL) score. Results: The IPSS and IPSS related QOL scores were significantly improved over the baseline score not for the LRP and ORP but for the RARP. For patients with moderate to severe LUTS preoperatively, the RARP group immediately improved in terms of preoperative LUTS differently from both LRP and ORP groups. Only RARP significantly improved in terms of voiding symptom composites (VSC) differently from both LRP and ORP procedures. However, none of the procedures changed in terms of storage symptom composites (SSC) longitudinally. Conclusions: The improvement of LUTS for RARP may contribute to the improvement of not only SSC but also VSC.

  WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020年, UROLOGICAL SCIENCE, 31(1) (1), 21 - 27, 国際共著していない

  [査読有り]


• Prevalence of hand joint symptoms in androgen deprivation therapy among japanese patients with prostate cancer

  Inoue, Shogo, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio

  Purpose: The current trends in favor of androgen deprivation therapy (ADT) for nonmetastatic prostate cancer at the stage of biochemical recurrence or increasing prostate-specific antigen levels raise the issue of exposing asymptomatic patients to potential adverse effects over the longer term. The aim of this study is to assess the hand joint symptoms caused by ADT in Japanese patients with prostate cancer. Materials and Methods: We retrospectively reviewed and performed a cross-sectional survey of hand joint symptoms in patients receiving ADT for prostate cancer. The results were compared with a control group of patients with prostate cancer that was hormone-naive group. In total, there were 279 Japanese patients with prostate cancer, of whom 150 patients were ADT treated and 129 patients were hormone naive. Patients completed a three-item self-administered questionnaire assessing the presence of hand joint symptoms that started or worsened after initiating ADT. Results: A statistically significant difference was found between the incidence rates of hand joint symptoms of both groups (P = 0.0056). There was a statistically significant difference in the incidence rates of hand joint pain (P = 0.0273). However, the incidence rates of hand numbness (P = 0.0576) and hand muscle weakness (P = 0.1098) between both groups were not significantly different. Conclusion: Our cross-sectional study demonstrated that patients receiving ADT for prostate cancer show significant hand joint symptoms compared to hormone-naive patients. Consequently, for patients receiving ADT who suffer from hand joint symptoms, we must consider the adverse effects of ADT.

  WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020年, UROLOGICAL SCIENCE, 31(1) (1), 15 - 20, 国際共著していない

  [査読有り]


• Current status of countermeasures for infectious diseases and resistant microbes in the field of urology

  Kitano, Hiroyuki, Teishima, Jun, Shigemura, Katsumi, Ohge, Hiroki, Fujisawa, Masato, Matsubara, Akio

  A worldwide increase in antimicrobial-resistant microbes due to the improper use of antimicrobial agents, along with a lack of progress in developing new antimicrobials, is becoming a societal problem. Although carbapenem-resistant Enterobacteriaceae, which are resistant to carbapenem antimicrobials, first appeared in 1993, treatment options remain limited. Mechanisms behind antimicrobial resistance involve changes to microbial outer membranes, drug efflux pump abnormalities, beta-lactamase production and the creation of biofilms around cell bodies. Genetic information related to these forms of antimicrobial resistance exists on chromosomes and plasmids, and when located on the latter can easily be transmitted to other strains, no matter the species, which creates a risk of antimicrobial resistance spreading exceptionally rapidly. To prevent the spread of antimicrobial resistance, the World Health Organization in 2015 published an action plan on antimicrobial resistance, based on which World Health Organization member countries have laid out specific policies and targets. Urinary tract infections are a type of healthcare-associated infection, and the sexually transmitted disease pathogen, Neisseria gonorrhoeae, has been included in a list of microbes that pose a risk to human health published by the US Centers for Disease Control and Prevention. Urologists face numerous problems when attempting to use antimicrobials properly, which is one method of dealing with antimicrobial resistance. Therefore, this article describes the current state of resistant microbes associated with urinary tract infections and countermeasures for antimicrobial resistance, including new antimicrobials.

  WILEY, 2019年12月, INTERNATIONAL JOURNAL OF UROLOGY, 26(12) (12), 1090 - 1098, 国際共著していない

  [査読有り]


• Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.

  Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, Shigeta M, Kobayashi K, Kajiwara M, Kadonishi Y, Tacho T, Matsubara A.

  Purpose There are no criteria for administering first- or second-generation anti-androgens (FGA and SGA, respectively) to patients with non-metastatic castration-resistant prostate cancer (nmCRPC). This study aimed to assess the efficacy of alternative FGA therapy in nmCRPC patients and the prognosis of these patients and to identify factors for predicting patients potentially responsive to FGA. Methods Data from 63 men with nmCRPC who underwent alternative FGA therapy (bicalutamide, flutamide, or chlormadinone acetate) as first-line therapy after failure of primary androgen-deprivation therapy (PADT) between 2004 and 2017 at Hiroshima University Hospital and affiliated hospitals were retrospectively investigated. The associations of clinicopathological parameters with overall survival (OS) and prostate-specific antigen (PSA) progression-free survival (PFS) of alternative FGA-treated patients were analyzed. Results Time to CRPC [p = 0.007, hazard ratio (HR) = 4.77], regional lymph node involvement at the diagnosis of CRPC (p = 0.022, HR = 2.42), and PSA-PFS of alternative FGA therapy <= 6 months (p = 0.020, HR = 2.39) were identified as prognostic factors using a multivariate analysis. Additionally, Cox proportional hazard models revealed that PSA nadir value > 1 ng/mL during PADT (p = 0.034, HR = 2.40) and time from starting PADT to PSA nadir <= 1 year (p = 0.047, HR = 1.85) were predictive factors for worse PSA-PFS in alternative FGA therapy. Conclusions Shorter time to CRPC, regional lymph node involvement, PSA nadir during PADT > 1 ng/mL, and time from starting PADT to PSA nadir <= 1 year might suggest the potential benefit of immediate commencement of SGA, compared to FGA administration after nmCRPC diagnosis.

  SPRINGER, 2019年09月, Int Urol Nephrol., 52(1) (1), 77 - 85, 国際共著していない

  [査読有り]


• Current status of prognostic factors in patients with metastatic renal cell carcinoma

  Teishima, Jun, Inoue, Shogo, Hayashi, Tetsutaro, Matsubara, Akio

  In recent years, the induction of novel agents, including molecular-targeted agents and immune checkpoint inhibitors, have dramatically changed therapeutic options and their outcomes for metastatic renal cell carcinoma. Several prognostic models based on the data of patients with metastatic renal cell carcinoma treated with targeted agents or cytokine therapy have been useful in real clinical practice. Serum or peripheral blood markers related to inflammatory response have been reported to be associated with their prognosis or therapeutic efficacy. In addition to them, investigation for novel predictive factors that represent the efficacy of agents, the risk of adverse events and the prognosis are required for the advance of therapeutic strategies. The present review discusses the conventional prognostic models and clinical factors, and recent advances of the identification of some of the most promising molecules as novel biomarkers for metastatic renal cell carcinoma.

  WILEY, 2019年06月, INTERNATIONAL JOURNAL OF UROLOGY, 26(6) (6), 608 - 617, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Endoscopic repair of the urinary bladder with magnetically labeled mesenchymal stem cells: Preliminary report

  Sadahide, Kosuke, Teishima, Jun, Inoue, Shogo, Tamura, Takayuki, Kamei, Naosuke, Adachi, Nobuo, Matsubara, Akio

  Introduction: Transurethral resection of a bladder tumor (TURBT) using a resectoscope has been standard treatment for bladder cancer. However, no treatment method promotes the repair of resected bladder tissue. The aim of this study was to examine the healing process of damaged bladder tissue after a transurethral injection of bone marrow mesenchymal stem cells (MSCs) into the bladder. An injection of magnetic MSCs meant that they accumulated in the damaged area of the bladder. Another aim of this study was to compare the acceleration effect of MSC magnetic delivery on the repair of bladder tissue with that of non-magnetic MSC injection. Methods: Using the transurethral approach to avoid opening the abdomen, electrofulguration was carried out on the anterior wall of the urinary bladder of white Japanese rabbits to mimic tumor resection. An external magnetic field directed at the injured site was then applied using a 1-tesla (T) permanent magnet. Twelve rabbits were divided into three groups. The 1 x 10(6) of magnetically labeled MSCs were injected into the urinary bladder with or without the magnetic field (MSC M+ and MSC M-groups, respectively), and phosphate-buffered saline was i

  ELSEVIER SCIENCE BV, 2019年06月, REGENERATIVE THERAPY, 10, 46 - 53, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.

  Yohei Sekino, Naoya Sakamoto, Akira Ishikawa, Ririno Honma, Yoshinori Shigematsu, Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Akio Matsubara, Wataru Yasui

  Cisplatin (CDDP)‑based combination chemotherapy is the standard for muscle‑invasive bladder cancer (MIBC). However, nearly all patients undergoing CDDP chemotherapy become refractory due to the development of CDDP resistance. Therefore, clarification of the mechanisms of CDDP resistance is urgently needed. The transcribed ultraconserved regions (T‑UCRs) are a novel class of non‑coding RNAs that are highly conserved across species and are associated with carcinogenesis and cancer progression. In addition, emerging evidence has shown the involvement of androgen receptor (AR) signals in urothelial carcinoma (UC) progression. The aim of the present study was to investigate the expression of transcribed ultraconserved region Uc.63+, and to analyze the effects of Uc.63+ on AR expression and CDDP resistance in UC. Quantitative reverse transcription‑polymerase chain reaction (qRT‑PCR) revealed that the expression of Uc.63+ was higher in UC tissues than that in non‑neoplastic bladder tissues and 15 types of normal tissue. An MTT assay revealed that Uc.63+ was involved in cell proliferation. Western blotting demonstrated that the expression of AR was disrupted by the overexpression or knockdown of Uc.63+ in AR‑positive UMUC3 cells. Furthermore, knockdown of Uc.63+ increased sensitivity to CDDP in UMUC3 cells. Conversely, overexpression of Uc.63+ had no effect on CDDP sensitivity in AR‑negative RT112 cells. Additionally, we observed that the expression of Uc.63+ was increased in CDDP‑resistant UMUC3 cells (UMUC3‑CR) in comparison with that in parental UMUC3 cells. Knockdown of Uc.63+ re‑sensitized the UMUC3‑CR cells to CDDP. These results indicated that Uc.63+ may be a promising therapeutic target to overcome CDDP resistance in UC.

  SPANDIDOS PUBL LTD, 2019年05月, Oncology reports, 41(5) (5), 3111 - 3118, 英語, 国際誌

  [査読有り]

  研究論文（学術雑誌）


• Longitudinal analysis of laparoendoscopic single-site adrenalectomy and conventional laparoscopic adrenalectomy regarding patient-reported satisfaction and cosmesis outcomes

  Inoue, Shogo, Hayashi, Testutaro, Hieda, Keisuke, Shinmei, Shunsuke, Teishima, Jun, Matsubara, Akio

  Background/Objective: To compare longitudinal patient-reported cosmesis of laparoendoscopic single-site adrenalectomy (LESS-A) to that of conventional laparoscopic adrenalectomy (CLA). Methods: A total of 23, 15, and 9 patients underwent transumbilical LESS-A (TU-LESS), subcostal LESS-A (SC-LESS), and CLA, respectively. A questionnaire was administered asking the patient to assess wound pain (0: not painful to 10: very painful), satisfaction (0: not satisfied to 10: very satisfied), and cosmesis (0: very ugly to 10: very beautiful) on the basis of a visual analogue scale. We mailed questionnaires to all patients who received LESS-A and CLA at postoperative 1, 3, 6, 9, and 12 months. Results: No significant differences were observed in the pain scores between TU-LESS, SC-LESS, and CLA at every time point. In the CLA group, the cosmesis and satisfaction scores were significantly lower at postoperative 3 months (p = 0.0033, 0.0130). There were no significant inter-group differences in the cosmesis score between the three groups after postoperative 6 months. However, the satisfaction score of SC-LESS decreased after postoperative 3 months and was significantly lower at postoperative 9

  ELSEVIER SINGAPORE PTE LTD, 2019年03月, ASIAN JOURNAL OF SURGERY, 42(3) (3), 514 - 519, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer

  Sekino, Yohei, Oue, Naohide, Koike, Yuki, Shigematsu, Yoshinori, Sakamoto, Naoya, Sentani, Kazuhiro, Teishima, Jun, Shiota, Masaki, Matsubara, Akio, Yasui, Wataru

  Kinesin family member C1 (KIFC1) is a minus end-directed motor protein that plays an essential role in centrosome clustering. Previously, we reported that KIFC1 is involved in cancer progression in prostate cancer (PCa). We designed this study to assess the involvement of KIFC1 in docetaxel (DTX) resistance in PCa and examined the effect of KIFC1 on DTX resistance. We also analyzed the possible role of a KIFC1 inhibitor (CW069) in PCa. We used DTX-resistant PCa cell lines in DU145 and C4-2 cells to analyze the effect of KIFC1 on DTX resistance in PCa. Western blotting showed that KIFC1 expression was higher in the DTX-resistant cell lines than in the parental cell lines. Downregulation of KIFC1 re-sensitized the DTX-resistant cell lines to DTX treatment. CW069 treatment suppressed cell viability in both parental and DTX-resistant cell lines. DTX alone had little effect on cell viability in the DTX-resistant cells. However, the combination of DTX and CW069 significantly reduced cell viability in the DTX-resistant cells, indicating that CW069 re-sensitized the DTX-resistant cell lines to DTX treatment. These results suggest that a combination of CW069 and DTX could be a potential str

  MDPI, 2019年02月, JOURNAL OF CLINICAL MEDICINE, 8(2) (2), 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Fibroblast Growth Factor Family in the Progression of Prostate Cancer

  Teishima, Jun, Hayashi, Tetsutaro, Nagamatsu, Hirotaka, Shoji, Koichi, Shikuma, Hiroyuki, Yamanaka, Ryoken, Sekino, Yohei, Goto, Keisuke, Inoue, Shogo, Matsubara, Akio

  Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance of tissue homeostasis and the development and differentiation of prostate tissue through epithelial-stromal interactions. Aberrations of this signaling are linked to the development and progression of prostate cancer (PCa). The FGF family includes two subfamilies, paracrine FGFs and endocrine FGFs. Paracrine FGFs directly bind the extracellular domain of FGFRs and act as a growth factor through the activation of tyrosine kinase signaling. Endocrine FGFs have a low affinity of heparin/heparan sulfate and are easy to circulate in serum. Their biological function is exerted as both a growth factor binding FGFRs with co-receptors and as an endocrine molecule. Many studies have demonstrated the significance of these FGFs and FGFRs in the development and progression of PCa. Herein, we discuss the current knowledge regarding the role of FGFs and FGFRs-including paracrine FGFs, endocrine FGFs, and FGFRs-in the development and progression of PCa, focusing on the representative molecules in each subfamily.

  MDPI, 2019年02月, JOURNAL OF CLINICAL MEDICINE, 8(2) (2), 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

  Sekino, Yohei, Oue, Naohide, Mukai, Shoichiro, Shigematsu, Yoshinori, Goto, Keisuke, Sakamoto, Naoya, Sentani, Kazuhiro, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Background Prostate cancer (PCa) is a common malignancy worldwide and is the second leading cause of cancer death in men. The standard therapy for advanced PCa is androgen deprivation therapy (ADT). Although ADT, including bicalutamide treatment, is initially effective, resistance to bicalutamide frequently occurs and leads to the development of castration-resistant PCa. Thus, clarifying the mechanisms of bicalutamide resistance is urgently needed. We designed this study to assess the expression and function of PCDHB9, which encodes the protocadherin B9 protein. Methods The expression of PCDHB9 was determined using immunohistochemistry and a qRT-PCR. The effects of the overexpression or knockdown of PCDHB9 on cell growth, migration, adhesion were evaluated. To evaluate the PCDHB9-mediated effects in PCa, we performed a gene expression analysis using DU145 transfected with PCDHB9. We examined the effects of PCDHB9 inhibition on bicalutamide resistance. Results The qRT-PCR revealed that the expression of PCDHB9 was much higher in PCa than that in non-neoplastic prostate tissues. In 152 clinically localized PCa cases immunohistochemistry showed that 59% of PCa cases were positive for

  WILEY, 2019年02月, PROSTATE, 79(2) (2), 234 - 242, 国際共著している

  [査読有り]

  研究論文（学術雑誌）


• SEC11A Expression Is Associated with Basal-Like Bladder Cancer and Predicts Patient Survival

  Shigematsu, Yoshinori, Oue, Naohide, Sekino, Yohei, Sakamoto, Naoya, Sentani, Kazuhiro, Uraoka, Naohiro, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Yasui, Wataru

  Objectives: Bladder cancer (BC) is a common malignancy worldwide. Signal peptidase complex 18 (SPC18) protein, which is encoded by the SEC11A gene, is one of the subunits of the signal peptidase complex and induces transforming growth factor-alpha secretion. In the present study, we analyzed the expression and function of SPC18 protein in human BC. Methods: Expression of SPC18 was analyzed by immunohistochemistry. RNA interference was used to inhibit SEC11A expression in BC cell lines. For constitutive expression of the SEC11A gene, a SEC11A expression vector was transfected into BC cell lines. To examine cell viability, we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Modified Boyden chamber assays were used to examine cell invasiveness. Results: SPC18 was upregulated in 54% of 81 BC cases. SPC18 expression served as an independent prognostic classifier of patients with BC. SPC18-positive BC cases frequently expressed cytokeratin 5/6, a marker of basal-like BC. Cell growth and invasiveness were inhibited by SEC11A knockdown and enhanced by forced expression of SEC11A. Conclusion: These results indicate that SPC18 plays an important role in th

  KARGER, 2019年, PATHOBIOLOGY, 86(4) (4), 208 - 216, 国際共著している

  [査読有り]

  研究論文（学術雑誌）


• Clinical features of prostate-specific antigen bounce after 125I brachytherapy for prostate cancer.

  Kubo K, Wadasaki K, Kimura T, Murakami Y, Kajiwara M, Teishima J, Matsubara A, Nagata Y.

  The aim of this study was to analyse the clinical features of prostate-specific antigen (PSA) bounce and the difference between biochemical failure and large-magnitude PSA bounce. The cases of 352 patients with prostate cancer who underwent brachytherapy were analysed. PSA bounce was defined as an increase in PSA of >= 0.2 ng/ml above an initial PSA nadir, with subsequent decline to or below that initial nadir without treatment. PSA bounce +2 was defined as an increase in PSA of >= 2.0 ng/ml above the nadir with subsequent decline to or below that initial nadir without treatment. We analysed the rates, time to onset, and predictive factors for PSA bounce and PSA bounce +2. The median follow-up period at the time of evaluation was 82 months. One hundred and seventeen patients had PSA bounce; of them, 10 had PSA bounce +2. Biochemical failure occurred in 29 patients. The median times to onset of PSA bounce, PSA bounce +2, and biochemical failure were 20, 17.5 and 51 months, respectively. Younger age at implant and larger prostate volume were significant predictive factors for PSA bounce. Age was a significant factor for PSA bounce +2, and PSA bounce +2 patients were significantly you

  OXFORD UNIV PRESS, 2018年09月, J Radiat Res., 59(5) (5), 649 - 655, 国際共著していない

  [査読有り][招待有り]

  研究論文（学術雑誌）


• Tubulocystic renal cell carcinoma: a review of literature focused on radiological findings for differential diagnosis

  Honda, Yukiko, Nakamura, Yuko, Goto, Keisuke, Terada, Hiroaki, Sentani, Kazuhiro, Yasui, Wataru, Sekino, Yohei, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Akagi, Motonori, Fuji, Tomoyo, Baba, Yasutaka, Iida, Makoto, Awai, Kazuo

  Tubulocystic renal cell carcinoma (TC-RCC) has been classified as an independent subtype according to the 2016 World Health Organization (WHO) classification. It is a rare subtype that predominantly affects men. Although few in number, radiological imaging reports have suggested that TC-RCC is characterized by multilocular cystic lesions, which are categorized as the Bosniak classification II-IV, with signature pathological characteristics comprising numerous small cysts or a tubular structure. The Bosniak classification system facilitates patient management; however, the differentiation of cystic tumors exhibiting similar imaging findings remains impossible; in fact, the differentiation of multilocular cystic RCC, adult cystic nephroma, and mixed epithelial and stromal tumor remains challenging. This review aims to discuss TC-RCC with a focus on implications of radiological findings in the differential diagnosis of TC-RCC.

  SPRINGER, 2018年07月, ABDOMINAL RADIOLOGY, 43(7) (7), 1540 - 1545

  [査読有り]

  研究論文（学術雑誌）


• Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival

  Jun Teishima, Shinya Ohara, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Hideki Mochizuki, Koji Mita, Masanobu Shigeta, Akio Matsubara

  Elsevier Inc., 2018年07月, Urologic Oncology: Seminars and Original Investigations, 36(7) (7), 339 - 339.e15, 英語

  [査読有り]

  研究論文（学術雑誌）


• Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.

  Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, Aoki M, Koga H, Satoh T, Ohashi T, Nakamura K, Katayama N, Tanaka N, Nakano M, Shigematsu N, Dokiya T, Fukushima M, J-POPS Investigators.

  2018年06月, Int J Clin Oncol., 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.

  Teishima J, Matsubara A.

  2018年06月, Int J Urol., 25(6) (6), 603 - 604, 国際共著していない

  [査読有り]


• Usefulness of personalized three-dimensional printed model on the satisfaction of preoperative education for patients undergoing robot-assisted partial nephrectomy and their families

  Jun Teishima, Yukihiro Takayama, Shogo Iwaguro, Tetsutaro Hayashi, Shogo Inoue, Keisuke Hieda, Shunsuke Shinmei, Ryoji Kato, Koji Mita, Akio Matsubara

  Springer Netherlands, 2018年06月, International Urology and Nephrology, 50(6) (6), 1061 - 1066, 英語

  [査読有り]

  研究論文（学術雑誌）


• Prospective study of robotic partial nephrectomy for renal cancer in Japan: Comparison with a historical control undergoing laparoscopic partial nephrectomy

  Kazushi Tanaka, Jun Teishima, Atsushi Takenaka, Ryoichi Shiroki, Yasuyuki Kobayashi, Kazunori Hattori, Hiro-Omi Kanayama, Shigeo Horie, Yasushi Yoshino, Masato Fujisawa

  Blackwell Publishing, 2018年05月, International Journal of Urology, 25(5) (5), 472 - 478, 英語

  [査読有り]

  研究論文（学術雑誌）


• Anastomosing haemangioma with fatty changes in the perirenal space: a lesion mimicking liposarcoma

  Kishida, Naotaka, Sentani, Kazuhiro, Terada, Hiroaki, Honda, Yukiko, Goto, Keisuke, Hatanaka, Yui, Kohashi, Kenichi, Oda, Yoshinao, Iwata, Jun, Yasui, Wataru, Shinmei, Shunsuke, Hayashi, Tetsutaro, Teishima, Jun, Matsubara, Akio, Nakamura, Yuko, Iida, Makoto, Awai, Kazuo

  Anastomosing haemangioma is a rare subtype of capillary haemangioma. Pathologically, anastomosing haemangioma presents with anastomosing sinusoidal capillary-sized vessels in an architecture reminiscent of the splenic parenchyma. Its anastomosing architecture pathologically can lead to concern for angiosarcoma. Many cases of anastomosing haemangioma, which often occurred in the retroperitoneum, were well circumscribed, hyperdense on plain CT, revealed avid contrast enhancement and some of them exhibited fatty changes. In cases of tumours with fat of retroperitoneal occurrence, images frequently do not allow for easy differentiation from liposarcoma. Although anastomosing haemangioma with fatty changes and liposarcoma can be difficult to differentiate, no previous report has addressed this diagnostic difficulty. We have encountered a case of anastomosing haemangioma with fatty changes occurring in the perirenal space that was difficult to differentiate from liposarcoma. With retroperitoneal tumours accompanied by fatty changes and including a strongly enhanced area, the possibility of anastomosing haemangioma-which is a benign tumour-may also be considered. In such cases, biopsy is

  BRITISH INST RADIOLOGY, 2018年, BJR CASE REPORTS, 4(2) (2), 20170022 - 20170022, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Transcribed ultraconserved region Uc.63+promotes resistance to docetaxel through regulation of androgen receptor signaling in prostate cancer

  Yohei Sekino, Naoya Sakamoto, Keisuke Goto, Ririno Honma, Yoshinori Shigematsu, Kazuhiro Sentani, Naohide Oue, Jun Teishima, Akio Matsubara, Wataru Yasui

  2017年11月, ONCOTARGET, 8(55) (55), 94259 - 94270, 英語

  [査読有り]

  研究論文（学術雑誌）


• The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

  Jun Teishima, Kohei Kobatake, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Shinya Ohara, Koji Mita, Yasuhisa Hasegawa, Satoshi Maruyama, Mitsuru Kajiwara, Masanobu Shigeta, Hideki Mochizuki, Hiroyuki Moriyama, Seiji Fujiwara, Akio Matsubara

  2017年11月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 35(11) (11), 英語

  [査読有り]

  研究論文（学術雑誌）


• Serous adenocarcinoma of retroperitoneum: a case report

  Kohada, Yuki, Teishima, Jun, Hattori, Yui, Kurimura, Yoshimasa, Fujii, Shinsuke, Sadahide, Kousuke, Fukuoka, Kenichiro, Ueno, Takeshi, Kitano, Hiroyuki, Goto, Keisuke, Hieda, Keisuke, Shinmei, Shunsuke, Sentani, Kazuhiro, Inoue, Shogo, Hayashi, Tetsutaro, Yasui, Wataru, Matsubara, Akio

  Primary retroperitoneal serous adenocarcinoma (PRSA) is an extremely rare malignancy, with only seven cases having been previously reported. We report a case of PRSA in a 42-year-old woman treated with surgical resection and adjuvant chemotherapy. The histopathological findings of PRSA resemble those of ovarian serous carcinoma, which indicates that a combination of complete surgical resection with adjuvant chemotherapy may be the best treatment option for PRSA.

  SPRINGER INTERNATIONAL PUBLISHING AG, 2017年10月, INTERNATIONAL CANCER CONFERENCE JOURNAL, 6(4) (4), 154 - 157, 英語, 国際誌, 国際共著している

  [査読有り]

  研究論文（学術雑誌）


• Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma

  Hiroyuki Kitano, Yasuhiko Kitadai, Jun Teishima, Ryo Yuge, Shunsuke Shinmei, Keisuke Goto, Shogo Inoue, Tetsutaro Hayashi, Kazuhiro Sentani, Wataru Yasui, Akio Matsubara

  2017年10月, CANCER MEDICINE, 6(10) (10), 2308 - 2320, 英語

  [査読有り]

  研究論文（学術雑誌）


• Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer

  Kohei Kobatake, Tetsutaro Hayashi, Peter C. Black, Keisuke Goto, Kazuhiro Sentani, Mayumi Kaneko, Wataru Yasui, Koji Mita, Jun Teishima, Akio Matsubara

  2017年08月, INTERNATIONAL JOURNAL OF UROLOGY, 24(8) (8), 594 - 600, 英語

  [査読有り]

  研究論文（学術雑誌）


• Imaging features of papillary renal cell carcinoma with cystic change-dominant appearance in the era of the 2016 WHO classification

  Yukiko Honda, Keisuke Goto, Yuko Nakamura, Hiroaki Terada, Kazuhiro Sentani, Wataru Yasui, Yohei Sekino, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Tomoyo Fuji, Yoko Kaichi, Toru Higaki, Yasutaka Baba, Makoto Iida, Kazuo Awai

  2017年07月, ABDOMINAL RADIOLOGY, 42(7) (7), 1850 - 1856, 英語

  [査読有り]

  研究論文（学術雑誌）


• Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer

  Yoshinori Shigematsu, Naohide Oue, Yuri Nishioka, Naoya Sakamoto, Kazuhiro Sentani, Yohei Sekino, Shoichiro Mukai, Jun Teishima, Akio Matsubara, Wataru Yasui

  2017年07月, ONCOLOGY LETTERS, 14(1) (1), 999 - 1004, 英語

  [査読有り]

  研究論文（学術雑誌）


• A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients

  Koichi Shoji, Jun Teishima, Tetsutaro Hayashi, Shunsuke Shinmei, Tomoyuki Akita, Kazuhiro Sentani, Yukio Takeshima, Koji Arihiro, Junko Tanaka, Wataru Yasui, Akio Matsubara

  2017年07月, ONCOLOGY LETTERS, 14(1) (1), 299 - 305, 英語

  [査読有り]

  研究論文（学術雑誌）


• Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels

  Goto, Keisuke, Nagamatsu, Hirotaka, Teishima, Jun, Kohada, Yuki, Fujii, Shinsuke, Kurimura, Yoshimasa, Mita, Koji, Shigeta, Masanobu, Maruyama, Satoshi, Inoue, Yoji, Nakahara, Mitsuru, Matsubara, Akio

  Prostate cancer, one of the most common malignant tumors among men, is closely associated with obesity and, thus far, several studies have suggested the association between obesity and aggressive pathological characteristics in the United States. However, the effect of obesity on prostate cancer mortality is controversial, and it remains unclear whether obesity contributes to the aggressiveness of prostate cancer in Asian patients. The aim of the present study was to investigate the association between body mass index (BMI) and the clinicopathological characteristics of prostate cancer in 2,003 Japanese patients who underwent radical prostatectomy. There was a significant association between higher BMI and higher Gleason score (GS). The multivariate analysis also revealed that BMI was an independent indicator for GS = 8 at surgery. Moreover, among patients with lower prostate-specific antigen levels, biochemical recurrence-free survival was significantly worse in those with higher BMI. These results suggest that BMI may be a classifier for predicting adverse pathological findings and biochemical recurrence after radical prostatectomy in Japanese patients.

  SPANDIDOS PUBL LTD, 2017年05月, MOLECULAR AND CLINICAL ONCOLOGY, 6(5) (5), 748 - 752, 英語, 国際誌, 国際共著していない

  [査読有り]

  研究論文（学術雑誌）


• Impact of neutrophil-to-lymphocyte ratio on effects of targeted therapy for metastatic renal cell carcinoma patients with extrapulmonary metastasis

  Jun Teishima, Shinya Ohara, Kousuke Sadahide, Shinsuke Fujii, Hiroyuki Kitano, Kohei Kobatake, Shunsuke Shinmei, Keisuke Hieda, Shogo Inoue, Tetsutaro Hayashi, Koji Mita, Akio Matsubara

  2017年05月, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 11(5) (5), E207 - E214, 英語

  [査読有り]

  研究論文（学術雑誌）


• Regeneration of rat corpora cavernosa tissue by transplantation of CD133(+) cells derived from human bone marrow and placement of biodegradable gel sponge sheet

  Shogo Inoue, Katsutoshi Miyamoto, Shunsuke Shinmei, Koichi Shoji, Jun Teishima, Kazuhiro Sentani, Wataru Yasui, Akio Matsubara

  2017年03月, ASIAN JOURNAL OF ANDROLOGY, 19(2) (2), 203 - 207, 英語

  [査読有り]

  研究論文（学術雑誌）


• A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial

  Tomomi Kamba, Toshiyuki Kamoto, Shinichiro Maruo, Takashi Kikuchi, Yosuke Shimizu, Shunichi Namiki, Kiyohide Fujimoto, Hiroaki Kawanishi, Fuminori Sato, Shintaro Narita, Takefumi Satoh, Hideo Saito, Mikio Sugimoto, Jun Teishima, Naoya Masumori, Shin Egawa, Hideki Sakai, Yusaku Okada, Toshiro Terachi, Osamu Ogawa

  2017年02月, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 22(1) (1), 166 - 173, 英語

  [査読有り]

  研究論文（学術雑誌）


• KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer

  Yohei Sekino, Naohide Oue, Yoshinori Shigematsu, Akira Ishikawa, Naoya Sakamoto, Kazuhiro Sentani, Jun Teishima, Akio Matsubara, Wataru Yasui

  2017年01月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 35(1) (1), 英語

  [査読有り]

  研究論文（学術雑誌）


• The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation

  K. Goto, S. Ishikawa, R. Honma, K. Tanimoto, N. Sakamoto, K. Sentani, N. Oue, J. Teishima, A. Matsubara, W. Yasui

  2016年07月, ONCOGENE, 35(27) (27), 3598 - 3606, 英語

  [査読有り]

  研究論文（学術雑誌）


• Effect of Spatial Cognitive Ability on Gain in Robot-Assisted Surgical Skills of Urological Surgeons

  Jun Teishima, Minoru Hattori, Shogo Inoue, Keisuke Hieda, Kohei Kobatake, Shunsuke Shinmei, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  2016年07月, JOURNAL OF SURGICAL EDUCATION, 73(4) (4), 624 - 630, 英語

  [査読有り]

  研究論文（学術雑誌）


• The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma

  Jun Teishima, Kohei Kobatake, Hiroyuki Kitano, Hirotaka Nagamatsu, Kousuke Sadahide, Keisuke Hieda, Shunsuke Shinmei, Koichi Shoji, Shogo Inoue, Tetsutaro Hayashi, Yoji Inoue, Shinya Ohara, Koji Mita, Akio Matsubara

  2016年06月, BJU INTERNATIONAL, 117(6B) (6B), E67 - E74, 英語

  [査読有り]

  研究論文（学術雑誌）


• A case of tubulocystic carcinoma of the kidney with aggressive features

  Yoko Maeda, Keisuke Goto, Yukiko Honda, Naoto Kuroda, Kazuhiro Sentani, Wataru Yasui, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Yuko Nakamura, Naoyuki Toyota, Makoto Iida, Kazuo Awai

  2016年04月, JAPANESE JOURNAL OF RADIOLOGY, 34(4) (4), 307 - 311, 英語

  [査読有り]

  研究論文（学術雑誌）


• Needlescopic-assisted laparoendoscopic single-site adrenalectomy

  Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2016年01月, ASIAN JOURNAL OF SURGERY, 39(1) (1), 6 - 11, 英語

  [査読有り]

  研究論文（学術雑誌）


• 新前立腺癌 最新の基礎研究と診断・治療 前立腺癌の分子生理学と発癌機序 前立腺癌の発癌・進展.

  2016年, 日本臨床, 74(3) (3), 80 - 86, 国際共著していない

  [招待有り]

  研究論文（学術雑誌）


• FGF19 Promotes Progression of Prostate Cancer

  Hirotaka Nagamatsu, Jun Teishima, Keisuke Goto, Hiroyuki Shikuma, Hiroyuki Kitano, Koichi Shoji, Shogo Inoue, Akio Matsubara

  2015年07月, PROSTATE, 75(10) (10), 1092 - 1101, 英語

  [査読有り]

  研究論文（学術雑誌）


• Population perception of surgical approach in minimally invasive surgery

  Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2015年01月, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 9(1-2) (1-2), E1 - E4, 英語

  [査読有り]

  研究論文（学術雑誌）


• ロボット時代の泌尿器科手術①-前立腺癌に対する新たなスタンダード Ⅱ.手術成績 性機能.

  亭島 淳, 稗田圭介, 井上省吾, 小畠浩平, 神明俊輔, 松原昭郎.

  2015年, 69(10) (10), 862 - 868, 国際共著していない

  [招待有り]

  研究論文（学術雑誌）


• 新時代の手術 ロボット支援根治的膀胱全摘除術

  亭島 淳

  2015年, 泌尿器外科, 28(3) (3), 281 - 285, 国際共著している

  [招待有り]

  研究論文（学術雑誌）


• 腎癌に対する腎部分切除術.

  亭島 淳

  2015年, 西日本泌尿器科, 77(2) (2), 43 - 51, 国際共著していない

  [査読有り][招待有り]

  研究論文（学術雑誌）


• Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method

  Shunsuke Shinmei, Kazuhiro Sentani, Tetsutaro Hayashi, Naoya Sakamoto, Keisuke Goto, Htoo Zarni Oo, Yutaka Naito, Jun Teishima, Akio Matsubara, Naohide Oue, Hiroki Kuniyasu, Wataru Yasui

  2014年08月, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 32(6) (6), 769 - 778, 英語

  [査読有り]

  研究論文（学術雑誌）


• Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

  Jun Teishima, Kohei Kobatake, Tetsutaro Hayashi, Yasuyuki Seno, Kenichiro Ikeda, Hirotaka Nagamatsu, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shogo Inoue, Kanao Kobayashi, Shinya Ohara, Mitsuru Kajiwara, Akio Matsubara

  2014年08月, ONCOLOGY LETTERS, 8(2) (2), 881 - 885, 英語

  [査読有り]

  研究論文（学術雑誌）


• 高齢者の排尿の治療 (シンポジウム 高齢化社会における泌尿器科の役割 : 今,泌尿器科に求められているもの)

  梶原 充, 亭島 淳, 松原 昭郎

  西日本泌尿器科学会, 2014年07月, 西日本泌尿器科 = The Nishinihon journal of urology, 76(7) (7), 218 - 224, 日本語, 国際共著していない

  研究論文（学術雑誌）


• Laparoendoscopic Single-Site Adrenalectomy sans Transumbilical Approach: Initial Experience in Japan

  Shogo Inoue, Kenichiro Ikeda, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2014年07月, UROLOGY JOURNAL, 11(4) (4), 1772 - 1776, 英語

  [査読有り]

  研究論文（学術雑誌）


• Retention of robot-assisted surgical skills in urological surgeons acquired using Mimic dV-Trainer

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Shinya Ohara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  2014年07月, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 8(7-8) (7-8), E493 - E497, 英語

  [査読有り]

  研究論文（学術雑誌）


• Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells

  Koichi Shoji, Jun Teishima, Tetsutaro Hayashi, Shinya Ohara, Wallace L. McKeehan, Akio Matsubara

  2014年07月, ONCOLOGY REPORTS, 32(1) (1), 65 - 70, 英語

  [査読有り]

  研究論文（学術雑誌）


• Rat Cavernous Nerve Reconstruction with CD133(+) Cells Derived from Human Bone Marrow

  Katsutoshi Miyamoto, Shogo Inoue, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2014年05月, JOURNAL OF SEXUAL MEDICINE, 11(5) (5), 1148 - 1158, 英語

  [査読有り]

  研究論文（学術雑誌）


• Therapeutic efficacy of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome

  Kajiwara, Mitsuru, Inoue, Shougo, Kobayashi, Kanao, Ohara, Shinya, Teishima, Jun, Matsubara, Akio

  Objectives: Narrow band imaging cystoscopy can increase the visualization and detection of Hunner's lesions. A single-center, prospective clinical trial was carried out aiming to show the effectiveness of narrow band imaging-assisted transurethral electrocoagulation for ulcer-type interstitial cystitis/painful bladder syndrome. Methods: A total of 23 patients (19 women and 4 men) diagnosed as having ulcer-type interstitial cystitis/painful bladder syndrome were included. All typical Hunner's lesions and suspected areas identified by narrow band imaging were electrocoagulated endoscopically after the biopsy of those lesions. Therapeutic efficacy was assessed prospectively by using visual analog scale score of pain, O'Leary-Sant's symptom index, O'Leary-Sant's problem index and overactive bladder symptom score. Results: The mean follow-up period was 22 months. All patients (100%) experienced a substantial improvement in pain. The average visual analog scale pain scores significantly decreased from 7.3 preoperatively to 1.2 1 month postoperatively. A total of 21 patients (91.3%) who reported improvement had at least a 50% reduction in bladder pain, and five reported complete resolutio

  WILEY-BLACKWELL, 2014年04月, INTERNATIONAL JOURNAL OF UROLOGY, 21, 57 - 60

  [査読有り]

  研究論文（学術雑誌）


• 女性の泌尿器科疾患

  梶原 充, 稗田圭介, 正路晃一, 宮本克利, 井上省吾, 小林加直, 大原慎也, 亭島 淳, 松原昭郎

  2014年03月, 産婦人科の実際, 63(3) (3), 421 - 426

  研究論文（学術雑誌）


• 症例報告 当院泌尿器科における膀胱膣瘻閉鎖術の3例

  梶原 充, 増本 弘史, 上野 剛志, 池田 健一郎, 井上 省吾, 稗田 圭介, 正路 晃一, 宮本 克利, 小林 加直, 亭島 淳, 浅野 耕助, 奥谷 卓也, 松原 昭郎

  広島医学会, 2014年03月, 広島医学, 67(3) (3), 201 - 205, 日本語, 国際共著していない

  研究論文（学術雑誌）


• Psychological factor, metacognition, is associated with the advantage of suturing techniques acquired on a virtual reality simulator of robot-assisted surgery

  Jun Teishima, Minoru Hattori, Akio Matsubara

  2014年03月, INTERNATIONAL JOURNAL OF UROLOGY, 21(3) (3), 349 - 350, 英語

  [査読有り]

  研究論文（学術雑誌）


• Accumulation of FGF9 in Prostate Cancer Correlates with Epithelial-to-Mesenchymal Transition and Induction of VEGF-A Expression

  Jun Teishima, Shigeki Yano, Koichi Shoji, Tetsutaro Hayashi, Keisuke Goto, Hiroyuki Kitano, Kiyotaka Oka, Hirotaka Nagamatsu, Akio Matsubara

  2014年02月, ANTICANCER RESEARCH, 34(2) (2), 695 - 700, 英語

  [査読有り]

  研究論文（学術雑誌）


• 全国アンケート結果

  妹尾 安子, 亭島 淳, 井上 省吾, 稗田 圭介, 松原 昭郎

  Japanese Society of Endourology, 2014年, Japanese Journal of Endourology, 27(2) (2), 241 - 245, 日本語

  研究論文（学術雑誌）


• Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate Cancer

  Keisuke Goto, Naohide Oue, Tetsutaro Hayashi, Shunsuke Shinmei, Naoya Sakamoto, Kazuhiro Sentani, Jun Teishima, Akio Matsubara, Wataru Yasui

  2014年, PATHOBIOLOGY, 81(4) (4), 190 - 198, 英語

  [査読有り]

  研究論文（学術雑誌）


• Patient-reported satisfaction and cosmesis outcomes following laparoscopic adrenalectomy: Laparoendoscopic single-site adrenalectomy vs. conventional laparoscopic adrenalectomy

  Shogo Inoue, Kenichiro Ikeda, Kanao Kobayashi, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2014年01月, CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 8(1-2) (1-2), E20 - E25, 英語

  [査読有り]

  研究論文（学術雑誌）


• Comparison of initial experiences of robot-assisted radical cystectomy with those of laparoscopic for bladder cancer

  Jun Teishima, Keisuke Hieda, Shogo Inoue, Keisuke Goto, Kenichiro Ikeda, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Akio Matsubara

  Lippincott Williams and Wilkins, 2014年, Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 9(4) (4), 322 - 326, 英語

  [査読有り]

  研究論文（学術雑誌）


• Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection.

  2014年, Can Urol Assoc J., 8(5.0) (5.0), 327 - 332

  [査読有り]

  研究論文（学術雑誌）


• MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma

  Shunsuke Shinmei, Naoya Sakamoto, Keisuke Goto, Kazuhiro Sentani, Katsuhiro Anami, Tetsutaro Hayashi, Jun Teishima, Akio Matsubara, Naohide Oue, Yasuhiko Kitadai, Wataru Yasui

  WILEY-BLACKWELL, 2013年05月, International Journal of Urology, 20(5) (5), 468 - 477, 英語

  [査読有り]

  研究論文（学術雑誌）


• 腎腫瘍に対する経腹膜的単孔式腹腔鏡手術

  井上 省吾, 梶原 充, 亭島 淳, 松原 昭郎

  低侵襲で優れた整容性が期待される術式として，2007年から単孔式腹腔鏡手術（laparoscopic single-site surgery； LESS surgery）が腎腫瘍において施行され，広島大学病院では2011年1月より腎細胞癌に対してLESSによる経腹膜的根治的腎摘除術（LESS腎摘除術）を開始した．11例の腎細胞癌に対してLESS腎摘除術を施行し，対象は男性6例，女性5例で平均年齢は54.9歳であった．患側は右4例，左7例で，最大腫瘍径の平均値は53.3mmであった．平均手術時間，出血量は175.5分，52.3mlで術中合併症を認めず，また従来法や開腹手術への移行なく手術を完遂した．同時期に当科で施行した20例の従来法との比較では，有意差は認めないがLESS腎摘除術の方が手術時間は短く出血量は少なかった．LESS腎摘除術では腎を取り出す際に5cm程度の皮膚切開が必要であるため，Parallel法を用いた従来法と同様の鉗子操作が可能になる．さらに経腹膜アプローチは後腹膜アプローチよりも操作腔が広く，従来法とほぼ同等の操作が可

  Japanese Society of Endourology, 2013年, Japanese Journal of Endourology, 26(1) (1), 62 - 67, 日本語

  研究論文（学術雑誌）


• ロボット支援腎部分切除術－経腹膜アプローチ

  亭島 淳, 松原 昭郎

  腹腔鏡下腎部分切除術における腫瘍切離および縫合操作は技術的難易度が高く克服すべき課題の1つである．広島大学病院泌尿器科では小径腎腫瘍に対し，ダヴィンチS-HDを用いた経腹膜的アプローチによるロボット支援腎部分切除術（RAPN）を導入した．これまで経験した5例の温阻血時間は14～25（中央値21）分で，全例，輸血，開腹移行をきたすことなく完遂し，翌日から経口摂取および歩行開始が可能であった．術後合併症も認めていない．ダヴィンチS-HDの持つ高解像度の3D視野，関節機能を有する鉗子，手ぶれ防止機能，TileProTMマルチ・ディスプレイによる画像の投影機能によって，RAPNでは従来の鏡視下手術に比較してより繊細かつ安定した手術操作が可能である．今後は従来の腹腔鏡下腎部分切除術では切除困難な症例に対するさらなる有用性が期待される．

  Japanese Society of Endourology, 2013年, Japanese Journal of Endourology, 26(1) (1), 7 - 12, 日本語

  研究論文（学術雑誌）


• Impact of Laparoscopic Experience on the Proficiency Gain of Urologic Surgeons in Robot-Assisted Surgery

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Katsutoshi Miyamoto, Koichi Shoji, Tetsutaro Hayashi, Kanao Kobayashi, Mitsuru Kajiwara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  2012年12月, JOURNAL OF ENDOUROLOGY, 26(12) (12), 1635 - 1638, 英語

  [査読有り]

  研究論文（学術雑誌）


• Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy

  Jun Teishima, Hideo Iwamoto, Katsutoshi Miyamoto, Koichi Shoji, Hiroshi Masumoto, Shogo Inoue, Kanao Kobayashi, Mitsuru Kajiwara, Akio Matsubara

  2012年12月, INTERNATIONAL JOURNAL OF UROLOGY, 19(12) (12), 1083 - 1089, 英語

  [査読有り]

  研究論文（学術雑誌）


• The search for secreted proteins in prostate cancer by the escherichia coli ampicillin secretion trap: Expression of NBL1 is highly restricted to the prostate and is related to cancer progression

  Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Shinya Ohara, Jun Teishima, Katsuhiro Anami, Naoya Sakamoto, Akio Matsubara, Wataru Yasui

  KARGER, 2012年11月, Pathobiology, 80(2) (2), 60 - 69, 英語

  [査読有り]

  研究論文（学術雑誌）


• 膀胱癌の新しい内視鏡的診断ツール ―i-scan, narrow band image―

  2012年05月, 広島医学別冊, 65(5) (5), 355 - 356

  [査読有り]

  研究論文（学術雑誌）


• Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence

  J. Teishima, K. Shoji, T. Hayashi, K. Miyamoto, S. Ohara, A. Matsubara

  2012年03月, PROSTATE CANCER AND PROSTATIC DISEASES, 15(1) (1), 8 - 14, 英語

  [査読有り]

  研究論文（学術雑誌）


• Comparison of Renal Function after Partial Nephrectomy and Radical Nephrectomy for Renal Cell Carcinoma

  Katsutoshi Miyamoto, Shogo Inoue, Mitsuru Kajiwara, Jun Teishima, Akio Matsubara

  2012年, UROLOGIA INTERNATIONALIS, 89(2) (2), 227 - 232, 英語

  [査読有り]

  研究論文（学術雑誌）


• Six-year experience of permanent prostate brachytherapy for clinically localized prostate cancer.

  2011年12月, 広島大学医学雑誌, 60(4) (4), 51 - 56

  [査読有り]

  研究論文（学術雑誌）


• Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma

  Tetsutaro Hayashi, Kazuhiro Sentani, Naohide Oue, Katsuhiro Anami, Naoya Sakamoto, Shinya Ohara, Jun Teishima, Tsuyoshi Noguchi, Hirofumi Nakayama, Kiyomi Taniyama, Akio Matsubara, Wataru Yasui

  2011年10月, HISTOPATHOLOGY, 59(4) (4), 710 - 721, 英語

  [査読有り]

  研究論文（学術雑誌）


• Identification of Transmembrane Protein in Prostate Cancer by the Escherichia coli Ampicillin Secretion Trap: Expression of CDON Is Involved in Tumor Cell Growth and Invasion

  Tetsutaro Hayashi, Naohide Oue, Naoya Sakamoto, Katsuhiro Anami, Htoo Zarni Oo, Kazuhiro Sentani, Shinya Ohara, Jun Teishima, Akio Matsubara, Wataru Yasui

  2011年, PATHOBIOLOGY, 78(5) (5), 277 - 284, 英語

  [査読有り]

  研究論文（学術雑誌）


• Dual segmental arterial supply to a single renal lobule: a study using semi-serial sections of mid-term fetuses

  Hiroaki Yasumoto, Ichiro Hirai, Atsushi Takenaka, Mineko Fujimiya, Gen Murakami, Wataru Kimura, Jun Teishima, Akio Matsubara

  2010年02月, BJU INTERNATIONAL, 105(3) (3), 416 - 421, 英語

  [査読有り]

  研究論文（学術雑誌）


• Restoration of FGF receptor type 2 enhances radiosensitivity of hormone-refractory human prostate carcinoma PC-3 cells

  Akio Matsubara, Jun Teishima, Suichinov Mirkhat, Hiroaki Yasumoto, Hideki Mochizuki, Mitsuhiro Seki, Kazuaki Mutaguchi, Wallace L. Mckeehan, Tsuguru Usui

  2008年07月, ANTICANCER RESEARCH, 28(4B) (4B), 2141 - 2146, 英語

  [査読有り]

  研究論文（学術雑誌）


• Inguinal hernia after radical perineal prostatectomy: Comparison with the retropubic approach

  Akio Matsubara, Tatsuaki Yoneda, Takahisa Nakamoto, Satoshi Maruyama, Syuntaro Koda, Keisuke Goto, Jun Teishima, Hiroaki Shiina, Mikio Igawa, Tsuguru Usui

  2007年12月, UROLOGY, 70(6) (6), 1152 - 1156, 英語

  [査読有り]

  研究論文（学術雑誌）


• Lower urinary tract symptoms after radical perineal prostatectomy

  Akio Matsubara, Tatsuaki Yoneda, Hiroaki Yasumoto, Jun Teishima, Hiroaki Shiina, Mikio Igawa, Koji Mita, Tsuguru Usui

  2007年07月, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 37(7) (7), 534 - 539, 英語

  [査読有り]

  研究論文（学術雑誌）


• DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer

  Yasuhisa Hasegawa, Akio Matsubara, Jun Teishima, Mitsuhiro Seki, Koji Mita, Tsuguru Usui, Naohide Oue, Wataru Yasui

  2007年01月, CANCER SCIENCE, 98(1) (1), 32 - 36, 英語

  [査読有り]

  研究論文（学術雑誌）


• Women's perception of male erectile dysfunction drugs in the general population.

  繁田 正信 梯 正之 松原 昭郎 亭島 淳 加藤 昌生 石 光広 長谷川 泰久 井上 洋二 碓井 亞

  2007年01月, Maturitas, 56(2) (2), 216 - 222

  [査読有り]

  研究論文（学術雑誌）


• 広島大学病院泌尿器科における体腔鏡下手術２１４例の臨床的検討

  三田 耕司 繁田 正信 碓井 亞 郷力 昭宏 井上 洋二 長谷川 泰久 石 光広 角西 雄一 亭島 淳 松原 昭郎

  日本泌尿器科学会西日本支部, 2006年09月, 西日本泌尿器科, 68(9) (9), 429 - 433, 日本語

  [査読有り]

  研究論文（学術雑誌）


• Lower urinary tract symptoms and risk of prostate cancer in Japanese men

  Akio Matsubara, Hiroaki Yasumoto, Jun Teishima, Mitsuhiro Seki, Koji Mita, Yasuhisa Hasegawa, Tateki Yoshino, Masao Kato, Tsuguru Usui

  2006年08月, INTERNATIONAL JOURNAL OF UROLOGY, 13(8) (8), 1098 - 1102, 英語

  [査読有り]

  研究論文（学術雑誌）


• Lower urinary tract symptoms and risk of prostate cancer in Japanese men

  Akio Matsubara, Hiroaki Yasumoto, Jun Teishima, Mitsuhiro Seki, Koji Mita, Yasuhisa Hasegawa, Tateki Yoshino, Masao Kato, Tsuguru Usui

  2006年08月, INTERNATIONAL JOURNAL OF UROLOGY, 13(8) (8), 1098 - 1102, 英語

  [査読有り]

  研究論文（学術雑誌）


• Impact of radical perineal prostatectomy on urinary continence and quality of life: A longitudinal study of Japanese patients

  A Matsubara, H Yasumoto, K Mutaguchi, K Mita, J Teishima, M Seki, M Kajiwara, M Kato, M Shigeta, T Usui

  2005年11月, INTERNATIONAL JOURNAL OF UROLOGY, 12(11) (11), 953 - 958, 英語

  [査読有り]

  研究論文（学術雑誌）


• Urological retroperitoneoscopic surgery for patients with prior intra-abdominal surgery

  K Mita, M Shigeta, K Mutaguchi, A Matsubara, T Yoshino, M Seki, H Mochizuki, M Kato, J Teishima, Y Kadonishi, H Yasumoto, T Usui

  2005年07月, EUROPEAN UROLOGY, 48(1) (1), 97 - 101, 英語

  [査読有り]

  研究論文（学術雑誌）


• 前立腺がんに対する125Ｉ密封小線源治療

  松原 昭郎 安本 博晃 三田 耕司 石 光広 亭島 淳 望月英樹 和田崎 晃一 権丈 雅浩 伊藤 勝陽

  2004年10月, 広島市医師会だより, 10, 15 - 19

  [査読有り]

  研究論文（学術雑誌）


• Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis

  H Mochizuki, A Matsubara, J Teishima, K Mutaguchi, H Yasumoto, R Dahiya, T Usui, K Kamiya

  2004年07月, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 320(3) (3), 656 - 663, 英語

  [査読有り]

  研究論文（学術雑誌）


• マウス肝癌で発現が亢進している新規遺伝子cis-retinol/androgen dehydrogenase type3 (CRAD3)の機能解析

  隅井 雅晴 山崎 岳 亭島 淳 小池則道 増田雄司 井倉 毅 小南 思郎 碓井 亞 神谷 研二

  2003年03月, ホルモンと臨床, 51(春季増刊) (春季増刊), 80 - 84, 日本語

  [査読有り]

  研究論文（学術雑誌）


• Genetic analysis of radiation-induced mouse hepatomas

  K Kamiya, M Sumii, Y Masuda, T Ikura, N Koike, M Takahashi, J Teishima

  2002年, RADIATION AND HOMEOSTASIS, PROCEEDINGS, 1236, 151 - 156, 英語

  研究論文（国際会議プロシーディングス）


• ヒト前立腺癌細胞株における繊維芽細胞成長因子７(KGF)とアンドロゲン受容体(AR)のクロストークに関する基礎的検討

  安本 博晃 松原 昭郎 亭島 淳 牟田口 和昭 碓井 亞

  2001年04月, ホルモンと臨床, 49, 180 - 183

  [査読有り]

  研究論文（学術雑誌）


• 放射線誘発マウス肝癌におけるIGFBP-7遺伝子の役割

  亭島 淳 安本 博晃 隅井 雅晴 増田雄司 福田三郎 高橋 護 小池則道 碓井 亞 神谷 研二

  2001年04月, ホルモンと臨床, 49(冬季増刊) (冬季増刊), 215 - 220

  [査読有り]

  研究論文（学術雑誌）


• Murine and human SDF2L1 is an endoplasmic reticulum stress-inducible gene and encodes a new member of the Pmt/rt protein family

  S Fukuda, M Sumii, Y Masuda, M Takahashi, N Koike, J Teishima, H Yasumoto, T Itamoto, T Asahara, K Dohi, K Kamiya

  2001年01月, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 280(1) (1), 407 - 414, 英語

  [査読有り]

  研究論文（学術雑誌）


• ヒトREV1遺伝子のクローニングと機能解析

  増田雄司, 隅井, 雅晴, 福田三郎, 高橋 護, 亭島, 淳, 小池則道, 神谷 研二

  2000年04月, 長崎医学会雑誌, 75(原爆特集) (原爆特集), 246 - 248

  [査読有り]

  研究論文（学術雑誌）

• 副作用の予防法と発症時の対応：口内炎、味覚障害、腎機能障害.

  編纂, 泌尿器ケア, 2012年09月

  学術書


• 手術手技：指導的助手からみた泌尿器科手術のポイント9 恥骨後式前立腺全摘除術（解説）

  編纂, 臨床泌尿器科, 2012年02月

  学術書

• バベンチオ＋インライタ併用療法を腎癌治療の現場で生かす

  亭島 淳

  第85回日本泌尿器科学会東部総会, 2020年, 日本語

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• Improved prognosis for old-aged patients with metastatic renal cell carcinoma after targeted therapy.

  Teishima J, Mita K , Shigeta M, Hasegawa Y, Kadonishi Y, Inoue S, Hayashi T , Matsubara A.

  34th Annual EAU Congress, 2019年, 英語, Barcelona

  口頭発表（一般）


• シンポジウム．広島県におけるがん・生殖医療ネットワークの現状と課題.

  亭島 淳, 井上 省吾, 林 哲太郎, 原 鐵晃, 一戸 辰夫, 松原 昭郎.

  第107 回日本泌尿器科学会総会, 2019年, 日本語, 名古屋

  シンポジウム・ワークショップパネル（指名）


• 腎細胞癌に対する最適な治療アプローチを考える. 「転移性腎細胞がん治療の薬剤選択」～めまぐるしい変化の中で～.

  亭島 淳

  第107 回日本泌尿器科学会総会, 2019年, 日本語, 名古屋

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• シンポジウム．内視鏡手術における周術期管理チームの役割．泌尿器科ロボット支援手術における術前から術後にかけてのチームの役割．

  亭島 淳、井上省吾、稗田圭介、林 哲太郎、松原昭郎.

  第32回日本内視鏡外科学会総会, 2019年, 日本語, 横浜

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• シンポジウム．ロボット支援腎部分切除術 高難度症例への挑戦．ロボット支援腎部分切除術の習熟と高難度症例への適応拡大．

  亭島 淳、井上省吾、稗田圭介、林 哲太郎、松原昭郎.

  第32回日本内視鏡外科学会総会, 2019年, 日本語, 横浜

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• Change of preoperative symptoms of late onset hypogonadism syndrome after robot-assisted radical prostatectomy.

  Teishima J, Inoue S, Hieda K, Shinmei S, Hayashi T, Matsubara A.

  13th Japan-Asean Conference on Men's Health and Aging, 2018年, 英語, 神戸

  口頭発表（一般）


• Prognostic impact of kinetics of C-reactive protein between before and after surgery in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy treated with tyrosine kinase inhibitor.

  Teishima J, Ohara S, Hieda K, Shinmei S, Inoue S, Hayashi T, Mochizuki H, Mita K, Matsubara A.

  2018 AUA Annual Meeting, 2018年, 英語, San Francisco

  口頭発表（一般）


• プロクタリングの実際―こんな時どうする― 2）機種による相違、注意点.

  亭島 淳

  第32回日本泌尿器内視鏡学会総会,第5回泌尿器ロボット支援手術プロクター教育セミナー, 2018年, 日本語, 仙台

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• 亭島 淳

  腎がん診療の現状と展望 TKIの特徴を活かした転移性腎細胞癌の治療戦略.

  第70回西日本泌尿器科学会総会, 2018年, 日本語, 長崎

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• ー転移性腎癌における免疫チェックポイント阻害剤と QOL-患者ごとに対応した最適な薬剤選択.

  亭島 淳

  日本性機能学会第29回学術総会, 2018年, 日本語, 神戸

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• FGF family in progression of prostate cancer.

  Teishima J, Hayashi T, Nagamatsu H, Shoji K, Goto K, Matsubara A.

  第5回前立線生物学シンポジウム伊勢志摩2018, 2018年, 日本語, 鳥羽

  [招待有り]

  口頭発表（招待・特別）


• ロボット支援前立腺全摘除術における解剖学的構造の再建.

  亭島 淳、井上省吾、稗田圭介、神明俊輔、林哲太郎、松原昭郎.

  第31回日本内視鏡外科学会総会, 2018年, 日本語, 福岡

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• ワークショップ．ロボット支援腎部分切除術のトラブルシューティング.

  亭島 淳, 井上 省吾, 稗田 圭介, 神明 俊輔, 林 哲太郎, 松原 昭郎

  第32回日本泌尿器内視鏡学会総会, 2018年, 日本語, 仙台

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• セッション3｢腎局所療法(腎癌難渋症例)｣ロボット支援腎部分切除術における高難度症例.

  亭島 淳、井上省吾、稗田圭介、神明俊輔、林哲太郎、松原昭郎.

  第4回泌尿器癌局所療法研究会, 2018年, 日本語, 岡山

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• 慢性腎臓病stageが腹腔鏡下・ロボット支援腎部分切除術の術後腎機能低下に及ぼす影響

  亭島 淳

  第68回西日本泌尿器科学会総会, 2016年11月, 日本語, 国内会議

  シンポジウム・ワークショップパネル（指名）


• シンポジウム３ 腹腔鏡下腎摘除（応用編）－ロボット支援腎部分切除術

  亭島 淳

  第30回日本泌尿器内視鏡学会総会, 2016年11月, 日本語, 国内会議

  シンポジウム・ワークショップパネル（指名）


• 腎盂尿管癌 診断と治療

  亭島 淳

  第81回日本泌尿器科学会東部総会 卒後教育プログラム, 2016年10月, 日本語, 国内会議

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• 分子標的薬を逐次投与された腎癌の予後における1st line薬剤の効果と中止理由の意義

  亭島 淳、大原慎也、藤井慎介、定秀孝介、北野弘之、稗田圭介、神明俊輔、井上省吾、林哲太郎、三田耕司、松原昭郎

  第54回日本癌治療学会学術集会, 2016年09月, 日本語, 国内会議

  シンポジウム・ワークショップパネル（公募）


• Regenerating islet-derived related protein 4 as a candidate of a novel biomarker in castration-resistant prostate cancer patients.

  J.Teishima, H. Nagamatsu, K.Shoji, R.Yamanaka, K.Kobatake, H.Kitano, K.Goto, T.Hayashi, N.Oue, W.Yasui, A.Matsubara.

  AUA 2016, 2016年05月, 英語, San Diego, 国際会議

  口頭発表（一般）


• 去勢抵抗性前立腺癌の治療

  亭島 淳

  第104回日本泌尿器科学会総会 卒後教育プログラム, 2016年04月, 日本語, 国内会議

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients.

  J. Teishima, H. Nagamatsu, K. Shoji, R. Yamanaka, K. Kobatake, H. Kitano, K. Goto, S. Shinmei, T. Hayashi, N. Oue, W. Yasui, A. Matsubara.

  31th EAU Congress, 2016年03月, 英語, Munch, 国際会議

  口頭発表（一般）


• 腎癌。Best of AUA in Japan 2015

  亭島 淳

  Best of AUA in Japan 2015, 2015年12月, 日本語, 東京都, 国内会議

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• RARPにおおける機能温存のコツ.

  亭島淳、井上省吾、小畠浩平、神明俊輔、稗田圭介、松原昭郎.

  第29回日本泌尿器内視鏡学会総会, 2015年11月, 日本語, 国内会議

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• ロボット支援腎部分切除術の導入と今後の課題.

  亭島淳、井上省吾、小畠浩平、神明俊輔、稗田圭介、松原昭郎.

  第29回日本泌尿器内視鏡学会総会, 2015年11月, 日本語, 国内会議

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• ロボット支援前立腺全摘除術における性機能温存

  亭島 淳

  第40回日本外科系連合学会学術集会, 2015年06月, 日本語, 国内会議

  [招待有り]

  シンポジウム・ワークショップパネル（指名）


• Impact of change in serum C-reactive protein level on the prediction of effects of molecular targetedtherapy in metastatic renal cell carcinoma patients.

  Teishima J, Kitano H, Kobatake K, Babasaki T, Nagamatsu H, Hieda K, Shinmei S, Goriki A, Shoji K, Inoue S, Kajiwara M, Mita K, Matsubara A.

  AUA 2015, 2015年05月, 日本語, New orleans, 国際会議

  口頭発表（一般）


• Impact of spatial cognitive ability on the proficiency of urological surgeons in robot-assisted surgery using mimic dV-trainer.

  Teishima J, Hattori M, Inoue S, Hieda K, Kobatake K, Egi H, Ohdan H, Matsubara A.

  AUA 2015, 2015年05月, 英語, New orleans, 国際会議

  口頭発表（一般）


• 転移性腎細胞癌に対する分子標的治療の効果予測におけるCRPの意義.

  亭島 淳、北野弘之、小畠浩平、永松弘孝、稗田圭介、正路晃一、井上省吾、梶原 充、三田耕司、松原昭郎

  第 103 回日本泌尿器科学会総会, 2015年04月, 日本語, 国内会議

  口頭発表（一般）


• Impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in metastatic renal cell carcinoma patients.

  Teishima J, Kitano H, Kobatake K, Babasaki T, Nagamatsu H, Hieda K, Shinmei S, Goriki A, Shoji K, Inoue S, Kajiwara M, Mita K, Matsubara A.

  30th EAU Annual Congress, 2015年03月, 英語, Madrid, 国際会議

  口頭発表（一般）


• Impact of spatial cognitive ability on the proficiency of urological surgeons in robot-assisted surgery using mimic dV-trainer.

  Teishima J, Hattori M, Inoue S, Hieda K, Kobatake K, Egi H, Ohdan H, Matsubara A.

  30th EAU Annual Congress, 2015年03月, 日本語, 国際会議

  口頭発表（一般）


• 『かかりつけ医のための泌尿器疾患診療のポイント』前立腺がんの治療と地域連携パス.

  亭島 淳

  日医生涯教育協力講座, 2015年03月, 日本語, 国内会議

  [招待有り]

  公開講演，セミナー，チュートリアル，講習，講義等


• 一般口演15「排尿機能・女性泌尿器」間質性膀胱炎ハンナー領域の同定におけるi-scanの有用性;narrow band imageとの比較研究

  梶原 充

  第79回日本泌尿器科学会東部総会, 2014年10月, 日本語, 日本泌尿器科学会, 横浜市, 国内会議


• 泌尿器科医におけるda Vinciの鉗子操作習得後のretentionについて

  亭島 淳

  第79回日本泌尿器科学会東部総会, 2014年10月, 日本語, 日本泌尿器科学会, 横浜市, 国内会議


• 単孔式腹腔鏡下副腎摘除術におけるラーニングカーブと手術難易度の術前予測

  井上省吾

  第27回日本内視鏡外科学会総会, 2014年10月, 日本語, 日本内視鏡外科学会, 盛岡市, 国内会議


• 広島大学における単孔式腹腔鏡下副腎摘除術の工夫 ―術式の標準化を目指して―

  井上省吾

  第27回日本内視鏡外科学会総会, 2014年10月, 日本語, 日本内視鏡外科学会, 盛岡市, 国内会議


• ロボット支援腹腔鏡下腎部分切除術の経験

  亭島 淳

  第27回日本内視鏡外科学会総会, 2014年10月, 日本語, 日本内視鏡外科学会, 盛岡市, 国内会議


• 低強度体外衝撃波（ED1000）によるED治療経験

  井上 省吾

  第14回日本Men's Health医学会, 2014年09月, 日本語, 日本Men's Health医学会, 千里市, 国内会議

  口頭発表（一般）


• 腎細胞癌Xenograft モデルにおける発光imaging についての検討

  北野弘之

  第73回日本癌学会学術総会, 2014年09月, 日本語, 日本癌学会, 横浜市, 国内会議


• Endocrine FGFs promote progression in prostate cancer.

  永松弘孝

  第73回日本癌学会学術総会, 2014年09月, 日本語, 日本癌学会, 横浜市, 国内会議


• 去勢抵抗性前立腺癌におけるregIVの意義

  亭島 淳

  第73回日本癌学会学術総会, 2014年09月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• 去勢抵抗性前立腺癌に対するドセタキセル療法の予後予測

  北野弘之

  第73回日本癌学会学術総会, 2014年09月, 日本語, 日本癌学会, 横浜市, 国内会議


• 演題1：当院におけるパゾパニブの使用経験.

  亭島淳

  広島県腎癌学術講演会, 2014年09月, 日本語, グラクソ・スミスクライン株式会社, 広島市, 座長, 国内会議


• 陰茎プレチスモグラフィを用いた低強度体外衝撃波治療効果の評価

  馬場崎隆志

  日本性機能学会第25回学術総会, 2014年09月, 日本語, 日本性機能学会, 仙台市, 国内会議


• 転移性腎細胞癌に対する分子標的治療の効果予測におけるCRPの意義

  亭島 淳

  第５２回日本癌治療学会学術集会, 2014年08月, 日本語, 日本癌治療学会, 横浜市, 国内会議

  口頭発表（一般）


• 単孔式腹腔鏡下左副腎摘除における先端屈曲型クリップアプライヤーの使用経験

  井上省吾

  3rd Reduced Port Surgery Forum in Fukui, 2014年08月, 日本語, 3rd Reduced Port Surgery Forum 2014 in Fukui運営事務局, 福井市, 国内会議


• 分子標的薬を投与された転移性腎細胞癌の治療効果予測におけるCRPの意義

  亭島 淳

  第45回腎癌研究会, 2014年07月, 日本語, 腎癌研究会, 東京都, 国内会議

  口頭発表（一般）


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生

  井上省吾

  第11回泌尿器科再建再生研究会, 2014年07月, 日本語, 泌尿器科再建再生研究会, 青森市, 国内会議


• FGF family in the progression of prostate cancer.

  Jun Teishima

  前立腺生物学シンポジウム 伊勢志摩2014, 2014年06月, 日本語, 鳥羽市, 国内会議

  シンポジウム・ワークショップパネル（指名）


• 腎部分切除術におけるRENAL nephrometry scoreを用いた術式別手術成績の評価

  重松慶紀

  第155回日本泌尿器科学会広島地方会, 2014年06月, 日本語, 日本泌尿器科学会広島地方会, 広島市, 国内会議

  口頭発表（一般）


• 一般演題：転移性腎細胞癌に対するスニチブの治療成績

  亭島 淳

  広島腎泌尿器科学講演会2014, 2014年06月, 日本語, ファイザー株式会社, 広島市, 座長, 国内会議

  その他


• Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance, and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells.

  Jun Teishima

  AUA Annual Meeting 2014, 2014年05月, 英語, AUA, Orland (USA), 国際会議

  口頭発表（一般）


• FGF19 subfamily promotes progression in prostate cancer cells.

  2014年05月, 英語, 国際会議

  口頭発表（一般）


• Restoration of Fibroblast Growth Factor Receptor 2IIIb Enhances the Chemosensitivity of Human Prostate Cancer Cells.

  Koichi Shoji

  AUA Annual Meeting 2014, 2014年05月, 英語, AUA, Orland(USA), 国際会議

  口頭発表（一般）


• Needlescopic-assisted laparoendoscopic single-site (LESS) adrenalectomy.

  Shogo Inoue

  AUA Annual Meeting 2014, 2014年05月, 英語, AUA, Orland (USA), 国際会議

  口頭発表（一般）


• わが国小学生を対象にしたインターネットリサーチを利用した過活動膀胱とQOLに関する疫学調査

  梶原 充

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• FGF19は前立線癌細胞の増殖を抑制する

  永松弘孝

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• 前立腺癌細胞におけるFGFR2Ⅲbの発現回復は化学療法感受性を増強する

  正路晃一

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• 低強度体外衝撃波(ED1000)によるED治療の検討

  井上省吾

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生の試み

  井上省吾

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• パネルディスカッション 単孔式ないしはリデュースポートサージェリー：安全性と整容性の両立単孔式腹腔鏡下副腎摘除術における整容性評価ー縦断的解析による従来法との比較ー

  井上 省吾

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  シンポジウム・ワークショップパネル（公募）


• 前立線癌におけるReg Ⅳの意義

  亭島 淳

  第102回日本泌尿器科学会総会, 2014年04月, 日本語, 日本泌尿器科学会総会, 神戸市, 国内会議

  口頭発表（一般）


• Regenerating islet-derived family, member 4 enhances cell proliferation, castration-resistance and chemoresistance through acceleration of neuroendocrine differentiation in human prostate cancer cells.

  J.Teishima

  29th Annual EAU Congress, 2014年04月, 英語, EAU, Stockholm(Sweden), 国際会議

  口頭発表（一般）


• FGF19 subfamily promotes orogression in prostate cancer.

  Nagamatsu H

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), 2014年03月, 英語, Asian Pacific Prostate Society (APPS), Okinawa(Japan), 国際会議

  口頭発表（一般）


• Prevalence of hand joint symptoms of androgen deprivation therapy.

  Shogo Inoue

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), 2014年03月, 英語, Asian Pacific Prostate Society (APPS), Okinawa( Japan), 国際会議

  口頭発表（一般）


• The role of regenerating islet-derived family, member 4 in human castration-resistant prostate cancer cells.

  Teishima J

  The 4th Congress of Asian Pacific Prostate Society (APPS2014), 2014年03月, 英語, Asian Pacific Prostate Society (APPS), Okinawa( Japan), 国際会議

  口頭発表（一般）


• 前立線癌の進行におけるRegⅣの役割

  亭島 淳

  第23回泌尿器科分子・細胞研究会, 2014年03月, 日本語, 泌尿器科分子・細胞研究会, 山形, 国内会議

  口頭発表（一般）


• ロボット支援腹腔鏡下腎部分切除術の経験

  亭島 淳

  第6回日本ロボット外科学会, 2014年02月, 日本語, 日本ロボット外科学会, 福岡市, 国内会議

  口頭発表（一般）


• ロボット支援手術での機器関連トラブルとその対処

  亭島 淳

  第22回中国四国前立線疾患研究会, 2014年02月, 日本語, 中国四国前立線疾患研究会, 岡山市, 国内会議

  公開講演，セミナー，チュートリアル，講習，講義等


• Notch2 promotes tumor growth and metastasis in bladder cancer: Notch2 inhibition is a rational treatment.

  Hayashi T

  2014 GU Cancers Symposium (ASCO GU), 2014年01月, 日本語, ASCO GU, San Francisco (USA), 国際会議

  口頭発表（一般）


• 針状細径鉗子（MiniLap）を使用した単孔式腹腔鏡下副腎摘除術の検討～ Needlescopic surgery との融合～

  井上省吾

  第10 回 Needlescopic Surgery Meeting, 2014年01月, 日本語, Needlescopic Surgery Meeting事務局, 鎌倉, 国内会議

  口頭発表（一般）


• ヒト骨髄由来CD133陽性細胞移植によるラット陰茎再生の試み

  井上省吾

  第24回日本性機能学会西部総会, 2014年01月, 日本語, 日本性機能学会, 山口市, 国内会議

  口頭発表（一般）


• ハンナー領域を伴う古典的間質性膀胱炎/膀胱痛症候群に対するnarrow-band imaging systemを用いた経尿道的焼灼術について

  梶原 充

  第13回日本間質性膀胱炎研究会, 2014年01月, 日本語, 日本間質性膀胱炎研究会, 東京, 国内会議

  口頭発表（一般）


• 広島大学におけるロボット支援根治的前立線全摘除術の初期成績

  亭島 淳

  第29回前立線シンポジウム, 2013年12月, 日本語, 公益財団法人前立腺研究財団, 東京, 国内会議

  口頭発表（一般）


• ワークショップ23 泌尿器科ロボット支援手術におけるトラブルシューティング

  亭島 淳

  第26回 日本内視鏡外科学会総会, 2013年11月, 日本語, 日本内視鏡外科学会総会, 福岡市, 国内会議

  シンポジウム・ワークショップパネル（指名）


• 単孔式腹腔鏡下副腎摘除術の現状と将来-Needlescopic Surgeryとの融合-

  井上省吾

  第26回日本内視鏡外科学会総会, 2013年11月, 日本語, 日本内視鏡外科学会総会, 福岡市, 国内会議

  口頭発表（一般）


• 単孔式腹腔鏡下副腎摘除術における針状細径鉗子の有用性

  井上省吾

  第27回日本泌尿器内視鏡学会総会, 2013年11月, 日本語, 日本泌尿器内視鏡学会総会, 名古屋市, 国内会議

  口頭発表（一般）


• 患者から見たLESSの評価-単孔式vs.従来法-

  井上省吾

  第27回日本泌尿器内視鏡学会総会, 2013年11月, 日本語, 日本泌尿器内視鏡学会総会, 名古屋市, 国内会議

  口頭発表（一般）


• 広島大学病院泌尿器科におけるロボット手術の取り組み

  稗田圭介

  第27回日本泌尿器内視鏡学会総会, 2013年11月, 日本語, 日本泌尿器内視鏡学会総会, 名古屋市, 国内会議

  口頭発表（一般）


• 前立腺癌の検出における光力学診断の有用性の検討

  小林加直

  第27回日本泌尿器内視鏡学会総会, 2013年11月, 日本語, 日本泌尿器内視鏡学会総会, 名古屋市, 国内会議

  口頭発表（一般）


• 総会賞ポスター2 腹腔鏡・ロボット 泌尿器科医におけるda Vinciの鉗子操作習得後のretentionについて

  亭島 淳

  第27回日本泌尿器内視鏡学会総会, 2013年11月, 日本語, 日本泌尿器内視鏡学会総会, 名古屋市, 国内会議

  口頭発表（一般）


• 筋層非浸潤性膀胱癌に対する膀胱内注入療法後の再発に喫煙が及ぼす影響

  西田健介

  第65回西日本泌尿器科学会総会, 2013年11月, 日本語, 西日本泌尿器科学会総会, 佐賀市, 国内会議

  口頭発表（一般）


• 前立腺癌患者における肥満と臨床病理学的因子の関連

  永松弘孝

  第65回西日本泌尿器科学会総会, 2013年11月, 日本語, 西日本泌尿器科学会総会, 佐賀市, 国内会議

  口頭発表（一般）


• 切迫性尿失禁を伴う過活動膀胱患者に対するフェソテロジン4mgの安全性、忍容性、有用性の検討

  梶原充

  第65回西日本泌尿器科学会総会, 2013年11月, 日本語, 西日本泌尿器科学会総会, 佐賀市, 国内会議

  口頭発表（一般）


• CAST 法により同定した前立腺癌新規バイオマーカーの OPHN1 は 前立腺癌の進展に関わる

  後藤 景介

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• 前立腺癌細胞における Reg IV の発現は細胞増殖および化学療法耐性を増強する

  岡 清貴

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• CAST 法により見いだされたPRL1の前立腺癌における発現と機能解析

  神明 俊輔

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• FGF19は前立腺癌細胞の増殖を促進する

  永松 弘孝

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• 前立線癌細胞におけるFGF2Ⅲbの発現回復は化学療法感受性を増強する

  正路 晃一

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• 前立腺癌細胞におけるFGF9の集積は上皮間葉移行およびVEGFAの誘導に関与する

  亭島 淳

  第72回日本癌学会学術総会, 2013年10月, 日本語, 日本癌学会, 横浜市, 国内会議

  口頭発表（一般）


• Oligophrenin-1 Is Associated with Cell Adhesion and Migration in Prostate Cancer.

  Goto K

  33rd Congress of the Societe internationale D'urologie(SIU2013), 2013年09月, 英語, the Societe internationale D'urologie(SIU), Vancouver( Canada), 国際会議

  口頭発表（一般）


• Restoration of Fibroblast Growth Factor Receptor 2Ⅲb Enhances the Chemosensitivity of Human Castration Resistant Prostate Cancer Cells

  2013年09月, 英語, 国際会議

  口頭発表（一般）


• Trastuzumab-DM1 (T-DM1) is highly effective in HER2-overexpressing bladder cancer.

  2013年09月, 英語, 国際会議

  口頭発表（一般）


• Notch-2 regulates growth, self-renewal and metastasis in invasive bladder cancer.

  Hayashi T

  33rd Congress of the Societe internationale D'urologie(SIU2013), 2013年09月, 英語, the Societe internationale D'urologie(SIU), Vancouver(Canada), 国際会議

  口頭発表（一般）


• The correlation of accumulated fibroblast growth factor 9 in prostate cancer cells with epithelial-mesenchymal transition and the induction of VEGFA expression.

  Teishima J

  2013年09月, 英語, 国際会議

  口頭発表（一般）


• 針状細径鉗子(MiniLap)を使用した単孔式腹腔鏡下左副腎摘除術の検討

  井上省吾

  Reduced Port Surgery Form in Morioka, 2013年07月, 日本語, 盛岡市, 国内会議

  口頭発表（一般）


• 転移性腎癌における非淡明細胞癌と淡明細胞癌の比較

  亭島 淳

  第44回腎癌研究会, 2013年07月, 日本語, 腎癌研究会, 東京, 国内会議

  口頭発表（一般）


• 広島大学病院におけるロボット支援手術の臨床的検討

  稗田圭介

  第153回日本泌尿器科学会広島地方会, 2013年06月, 日本語, 日本泌尿器科学会広島地方会, 広島市, 国内会議

  口頭発表（一般）


• 低強度体外衝撃波(ED1000)によるED治療の初期経験

  井上省吾

  第153回日本泌尿器科学会広島地方会, 2013年06月, 日本語, 日本泌尿器科学会広島地方会, 広島市, 国内会議

  口頭発表（一般）


• ヒト骨髄由来 CD133 陽性細胞を用いたラット陰茎海綿体神経の再生

  宮本克利

  第10回泌尿器科再建再生研究会, 2013年06月, 日本語, 泌尿器科再建再生研究会, 東京, 国内会議

  口頭発表（一般）


• Usefulness of Flomoxef in the Prevention of Infection Complicating Transrectal Prostate Needle Biopsy.

  Kanao Kobayashi

  第28回国際化学治療法学会, 2013年06月, 英語, 国際化学療法学会(ICC), yokohama, 国際会議

  口頭発表（一般）


• Cavernous nerve reconstruction after transplantation to rats of CD133+cells delived from human bone marrow

  Katsutoshi Miyamoto

  The 14th Biennial Meeting of the Asia-Pacific Society for Sexual Medicine, 2013年05月, 英語, the Asia-Pacific Society for Sexual Medicine, kanazawa, 国際会議

  口頭発表（一般）


• Low Intergrative Extracorpopreal Shock Wave Therapy for Erectile Dysfunction in ED patients: Initial Experience in Japan

  Shogo Inoue

  The 14th Biennial Meeting of the Asia-Pacific Society for Sexual Medicine, 2013年05月, 英語, Asia-Pacific Society for Sexual Medicine, kanazawa( Japan), 国際会議

  口頭発表（一般）


• TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target

  Hayashi Tetsutaro

  AUA 2013 Annual Meeting, 2013年05月, 英語, AUA, San Diego( USA), 国際会議

  口頭発表（一般）


• Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients

  Shogo Inoue

  AUA 2013 Annual Meeting, 2013年05月, 英語, AUA, San Diego(USA), 国際会議

  口頭発表（一般）


• Patient-Reported Satisfaction and Cosmesis Outcomes Following Laparoscopic Adrenalectomy: LESS vs. Conventional Laparoscopic Surgery

  Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Koichi Shoji, Katsutoshi Miyamoto, Shinya Ohara, Kanao Kobayashi, Mitsuru Kajiwara, Juna Teishima, Akio Matsubara

  AUA 2013 Annual Meeting, 2013年05月, 英語, AUA, San Diego (USA), 国際会議

  口頭発表（一般）


• Prognositic Significance of C-reactive Protein in Intermediate-risk Japanese Metastatic Renal Cell Carcinoma Patients Treated with Molecular Targeted Therapy

  Teishima Jun

  2013年05月, 英語, 国際会議

  口頭発表（一般）


• The psychological factor, metacognition, is associated with the advantage of learning suturing techniques in robot-assisted surgery.

  Teishima Jun

  AUA 2013 Annual Meeting, 2013年05月, 英語, AUA, San Diego (USA), 国際会議

  口頭発表（一般）


• Fibroblast Growth Factor 9 in Prostate Cancer Cells is Associated With Postoperative Recurrence Through Accelearation of Mesenchymal Transition, Proliferation, and Invasion

  Jun Teishima

  AUA 2013 Annual Meeting, 2013年05月, 英語, AUA, San Diego (USA), 国際会議

  口頭発表（一般）


• 腫瘍型間質性膀胱炎/膀胱痛症候群の治療におけるnarro-band imaging systemを用いた経尿道的焼灼術の有用性について

  梶原充, 池田健一郎, 稗田圭介, 井上省吾, 小林加直, 大原慎二, 亭島淳, 松原昭郎

  梶原充, 池田健一郎, 稗田圭介, 井上省吾, 小林加直, 大原慎二, 亭島淳, 松原昭郎, 2013年04月, 日本語, 日本泌尿器科学会総会, 札幌

  口頭発表（一般）


• Significance of Metacognition in Urological Surgeons on the Proficiency Gain Process for Robot-assisｔed Surgery Evaluated by Using Mimic dV-Trainer.

  Jun Teishima, Minoru Hattori, Shogo Inoue, Kenichiro Ikeda, Keisuke Hieda, Shinya Ohara, Hiroyuki Egi, Hideki Ohdan, Akio Matsubara

  3rd Asian Pacific Prostate Society meeting Scientific Program, 2013年04月, 英語, Asian Pacific Prostate Society, Melbourne(Australia), 国際会議

  口頭発表（一般）


• ヒト骨髄由来 CD133 陽性細胞を用いたラット陰茎海綿体神経の再生

  宮本克利, 井上省吾, 池田健一郎, 稗田圭介, 正路晃一, 小林加直, 大原慎也, 梶原充, 亭島淳, 松原昭郎

  第101回日本泌尿器科学会総会, 2013年04月, 日本語, 日本泌尿器科学会総会, 札幌

  口頭発表（一般）


• 被爆者前立線癌の臨床病理学的特徴と予後ー非被爆者との比較

  正路晃一, 亭島淳, 林哲太郎, 神明俊輔, 秋田智之, 仙谷和弘, 武島幸男, 有広光司, 田中純子, 安井弥, 松原昭郎

  被爆者前立線癌の臨床病理学的特徴と予後ー非被爆者との比較, 2013年04月, 日本語, 日本泌尿器科学会総会, 札幌, 国内会議

  口頭発表（一般）


• 腎癌患者の予後における被爆の影響

  池田健一郎

  第101回日本泌尿器科学会総会, 2013年04月, 日本語, 日本泌尿器科学会総会, 札幌, 国内会議

  口頭発表（一般）


• 心理学的因子がda Vinciの鉗子操作習得に及ぼす影響

  亭島淳, 服部稔, 池田健一郎, 稗田圭介, 正路晃一, 宮本克利, 井上省吾, 小林加直, 大原慎也, 梶原充, 松原昭郎

  第101回日本泌尿器科学会総会, 2013年04月, 日本語, 日本泌尿器科学会総会, 札幌, 国内会議

  口頭発表（一般）


• 広島大学病院泌尿器科におけるロボット支援腎部分切除術

  亭島 淳

  第48回泌尿器科手術手技関東地区研究会, 2013年02月, 日本語, 国内会議

  口頭発表（招待・特別）


• 転移性腎細胞癌に対するエベロリムスを用いたseqential therapy ー広島大学病院における経験ー

  亭島 淳

  CORE-J 2012, 2012年09月, 日本語, 国内会議

  口頭発表（招待・特別）


• Usefulness of morphological classification of clinical T1 renal cell cancer on predicting upstaging to pathological T3 or higher.

  Teishima J, Hayashi T, Kitano H, Sadahide K, Shinmei S, Inoue S, Honda Y, Sentani K, Awai K, Yasui W, Matsubara A.

  2018 AUA Annual Meeting, 英語, San Francisco

  口頭発表（一般）


• Prediction for early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

  Teishima J, Hayashi T, Inoue S, Fujii S, Ikeda K, Goto K, Matsubara A.

  35th Annual EAU Congress, 英語

  口頭発表（一般）

• 去勢抵抗性前立腺癌オルガノイドの樹立とその解析による個別化医療の確立

  亭島 淳

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究C, 広島大学, 2018年 - 2021年, 研究代表者

  正常前立腺組織、限局性前立腺癌組織、去勢抵抗性前立腺癌組織（CRPC）由来のオルガノイドを樹立した。これらのオルガノイドおよび前立腺癌細胞株を用いて、KIFC1、MAPT、TUBB3、BUB1B、procadherrin B9などの分子群を介した、CRPCにおける薬剤耐性の分子機構を明らかにした。これらの組織における超転写保存領域（T-UCR）、およびそれによって発現が制御されるマイクロRNA群発現について、オルガノイドにおける相違を確認した。これらの分子群およびT-UCRの解析によって得られた知見について他癌種においても解析し確認した。

  競争的資金


• 去勢抵抗性前立腺癌オルガノイドの樹立とその解析による個別化医療の確立

  亭島 淳

  日本学術振興会, 科学研究費助成事業(基盤研究(C)), 2018年 - 2020年, 研究代表者

  競争的資金


• 尿路上皮がんの抗がん剤耐性におけるp38 MAPKの役割と新規阻害薬の応用開発

  神明俊輔

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 2017年 - 2020年

  p38の尿路上皮癌における化学療法耐性および治療標的としての意義を明らかにすることを目標に、臨床病理検体を用いたp38およびリン酸化p38の発現を検討した。STAT1シグ ナルは抗がん剤耐性膀胱癌で亢進し、細胞周期の抑制によって抗がん剤耐性獲得に関与する一方で、抗がん剤併用でのSTAT1発現抑制は抗がん剤感受性を回復させることから、抗がん剤とSTAT1抑制の併用 療法は抗がん剤耐性を克服する新規治療法となる可能性があると考えている。

  競争的資金


• Jmjd3過剰発現マウスを用いたエピジェネティックな前立腺癌発症機序の解明

  岩本秀雄

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 2017年 - 2019年

  前立腺癌においてJMJD3の過剰発現は、発症のみならず進展にも関与する事が示唆されているが、そのメカニズムは全く解明されていない。そこで我々は、Jmjd3前立腺特異的過剰発現（cKI)マウスおよび、Jmjd3と同じヒストンH3K27脱メチル化酵素であるKDM6A（UTX）前立腺特異的ノックアウトマウスを作製し、表現型獲得を試みた。しかしながら、いずれのマウスにおいても、前立腺には病理組織学的異常を認めなかった。 我々の研究結果は、前立腺癌発症において、エピジェネティックな因子のうち少なくともH3K27メチル化異常の関与する可能性は低い事を示唆している。

  競争的資金


• アンドロゲン応答性の転写超保存領域を標的とした前立腺かん新規診断・治療法の開発

  稗田圭介

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 広島大学, 2017年 - 2019年

  Uc.63+の強制発現させたLNCaPではドセタキセル耐性が亢進した。またアンドロゲン受容体の発現のないDU145ではUc.63+をノックダウンさせてもドセタキセル耐性は特に変化は認められず、これらの結果よりUc.63+はアンドロゲン受容体を介して、ドセタキセル耐性に関わっていることが示唆された。 血清中のUc.63+は限局性前立腺癌に比べ、転移性前立腺癌で高発現していた。また転移性前立腺癌の中でドセタキセル治療を受けた27例でUc.63+の発現を検討したところ、Uc.63+はDTX効果不良群で有意に発現が高く、Uc.63+高発現群は有意に予後不良であった。

  競争的資金


• 磁気ターゲティングを用いた骨髄幹細胞移植による膀胱再生の開発

  井上省吾

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 広島大学, 2016年 - 2019年

  磁気ターゲティングを用いた磁性体化骨髄間葉系幹細胞による組織再生を検証することを本研究の目的とした。オス日本白色家兎に対して、膀胱前壁に電気凝固を施行し、膀胱損傷モデルを作成した。膀胱内に1×106個の磁性体化骨髄間葉系幹細胞を注入し、腹壁に1Tの永久磁石を10分間当てることで膀胱前壁に磁性体化骨髄間葉系幹細胞を誘導した。MRIによる画像評価やHE染色やαSMA染色による組織学的評価において、対照群と比較して有意な膀胱組織再生を認めた。磁気ターゲティングを用いた磁性体化骨髄間葉系幹細胞による組織再生は膀胱組織損傷に対して有効な治療となりうる可能性が示唆された。

  競争的資金


• Dual-Energy CT による構成元素解析に着目した腎病変CT診断法の開発

  本田由紀子

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 広島大学, 2016年 - 2019年

  本研究では、Dual-Energy CTから腎病変診断に有用な、”鉄“、”脂肪“の画像解析、臨床応用が目的であった。ファントム実験を行い、鉄、脂肪を様々な割合で混合させ、CT画像のデータから解析を試みた。解析は可能であったが、鉄、脂肪の含有量が低いと誤差が生じ、解析不能であった。そこで実際の症例では、鉄の含有量が高い、出血に注目し、出血のある腫瘍とないものの区別を試みたが、出血の分布が均一ではなく、有意差のある結果に至らなかった。現在、取得したデータから、臨床に有用な解析ができないか試行錯誤を続けるも、有意差のある結果には至っていない。

  競争的資金


• 去勢抵抗性前立腺癌マーカーRegⅣ・OLFM4を標的とした新規診断・治療開発

  松原昭郎

  文部科学省, 科学研究費助成事業（基盤研究（C）, 基盤研究（C）, 広島大学, 2016年 - 2018年

  RegⅣの前立腺癌における血清マーカーおよび治療標的としての意義を明らかにすることを目標に、臨床病理検体を用いたRegⅣ・OLFM4の発現を検討した。血清RegⅣ値は、Stageが進行した症例や、去勢抵抗性前立腺癌の症例で高発現し、血清腫瘍マーカーとしての有効性が確認された。さらに血清でRegⅣ値が上昇していた症例は組織免疫組織染色法でもRegⅣの高発現が確認された。また、RegⅣの過剰発現が抗がん剤（ドセタキセルと5FU）への抵抗性獲得に関与していることをin vitroで確認した。

  競争的資金


• がん幹細胞性制御遺伝子を標的とした膀胱癌の新規治療法の開発

  林哲太郎

  文部科学省, 科学研究費助成事業（基盤研究（C））, 基盤研究（C）, 広島大学, 2016年 - 2018年

  抗がん剤耐性膀胱癌で、IFN/STAT1シグナルの遺伝子の高発現が認められた。抗がん剤耐性株のSTAT1発現抑制は細胞増殖能を亢進させ、細胞周期解析でもG1期減少とS期増加を認めた。一方で、シスプラチンもしくはゲムシタビン投与下で耐性株のSTAT1発現抑制を行うと、細胞増殖能は有意に抑制され、アポトーシスが増加した。STAT1シグナルは抗がん剤耐性膀胱癌で亢進し、細胞周期の抑制によって抗がん剤耐性獲得に関与する。一方で、抗がん剤併用でのSTAT1発現抑制は抗がん剤感受性を回復させることから、抗がん剤とSTAT1抑制の併用療法は薬剤耐性を克服する新規治療法となる可能性があると考えた。

  競争的資金


• 内分泌性FGFsの分子機構解明による去勢抵抗性前立腺癌に対する新規治療戦略の確立

  亭島 淳

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 広島大学, 2015年 - 2017年, 研究代表者

  去勢抵抗性前立腺癌（CRPC）症例における内分泌性FGF（FGF19、21、23）血中濃度と組織における発現を、ホルモン感受性前立腺癌、他の泌尿器癌と比較した。CRPC組織におけるFGF19、FGF21の集積亢進を認め、CRPC症例ではFGF19、FGF21の血清濃度がCRPC特異的に有意に高値であり、薬物療法による転移巣の縮小と関連して有意に低下がみられた。また、内分泌性FGF関連分子群の発現制御機構の解析によって、non-coding RNAを介した関連分子群の発現調節とそれに伴う薬剤感受性の変化を明らかにした。

  競争的資金


• メタボリック症候群と前立腺癌に関与するＦＧＦの分子機構解明と新たな治療戦略確立

  亭島 淳, 松原 昭郎, 井上 省吾, 正路 晃一

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 松原 昭郎;井上 省吾;正路 晃一, 2012年 - 2014年, 研究代表者

  昨年度に引き続き、前立腺全摘除術により得られた前立腺癌組織についてFGF19、FGF21、に対する抗体を用いた免疫組織化学染色をさらに検体数を増やし抗体を変えて行い、①FGF19サブファミリーの発現と再発、再燃の有無などの臨床経過や患者の基礎疾患の有無、病理組織学的所見との関連について検討した。FGF19は正常前立腺上皮、高分化癌組織に比較して分化度の低い癌組織で発現の上昇がみられた。また、FGF19陽性、FGF21陽性はFGF9陽性と同様に術後生化学的再発の独立した予測因子となりうることが明らかとなった。 前立腺癌細胞株LNCaP、DU145、PC3について、FGF19、21ならびにFGF9を添加した状態での細胞増殖への影響をMTT assayで解析、さらにこれらFGFファミリーの刺激により誘導される分子群についてウェスタンブロット法により解析した。FGF19刺激ではFGF9で刺激した場合と同様に、細胞増殖能の促進、抗アポトーシス効果、上皮間葉移行の促進がみられ、IGF添加によるこれらの作用の相

  競争的資金


• 前立腺癌の神経内分泌分化に関わる新規バイオマーカーの同定と診断・治療への応用

  松原 昭郎, 亭島 淳, 安井 弥, 井上 省吾

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 亭島 淳;安井 弥;井上 省吾, 2012年 - 2014年, 連携研究者

  昨年度にひき続き、神経内分泌癌の発生に関与する分子を探索し、RegIVとFGFR2に焦点を当てて研究を進めた。昨年度作成したRegIVおよびＦGFR2安定発現PC3に加えて、LNCaPについてもRegIVの安定発現株を作成した。RegIV安定発現LNCaPではシナプトピジン、NSE、クロモグラニンAをはじめとする神経内分泌マーカーおよびVEGFAをはじめとする血管新生因子の発現誘導が認められ、NCadの増強とECadの減弱が認められ、アンドロゲン除去下での増殖能亢進が認められた。さらに血清RegIV濃度をELISA法で測定したところ、非癌症例群に比較してホルモン依存性前立腺癌症例群、この2群に比較して去勢抵抗性前立腺癌症例群において有意にRegIV濃度が高値であった。また、前立腺原発神経内分泌癌組織においてRegIVの発現増強が確認された。 これまでの研究成果の一部は、第72回日本癌学会学術総会（札幌）、第23回泌尿器分子細胞研究会で発表した。

  競争的資金


• CAST法による前立腺癌の分泌・膜蛋白検索と診断・治療への応用

  松原 昭郎, 亭島 淳, 安井 弥, 林 哲太郎, 大原 慎也, 井上 省吾

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 亭島 淳;安井 弥;林 哲太郎;大原 慎也;井上 省吾, 2009年 - 2011年, 連携研究者

  前立腺癌細胞株とヒト正常前立腺組織からCASTライブラリーのスクリーニングにより、前立腺癌に特異的な膜貫通タンパクもしくは分泌タンパクをコードする候補遺伝子群を同定、そのうちCDONとNBL1は前立腺癌において正常前立腺組織に比較して特に高発現が認められた。これらの蛋白は前立腺癌の標的分子となりうる可能性が示唆され、DSC2については尿路上皮癌の扁平上皮癌化のマーカーであることを明らかにした.

  競争的資金


• 前立腺癌のホルモン依存性消失におけるFGF受容体の関わりと新しい治療法への応用

  松原 昭郎, 安本 博晃, 亭島 淳, 三田 耕司, 大原 慎也, 長谷川 泰久

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 安本 博晃;亭島 淳;三田 耕司;大原 慎也;長谷川 泰久, 2007年 - 2008年, 連携研究者

  本研究者らはホルモン不応性前立腺がんに対してチロシンキナーゼの1つFGFR2を移入することによって増殖が有意に抑制されると共にホルモン依存性の特性を部分的に回復する実験結果をもとに、これまでホルモン不応性前立腺がんに対するFGFR2導入療法の前臨床試験を行ってきた。一方、ホルモン不応性前立腺がんとFGFR2の遺伝子変異の関係も合わせて検討してきたが、現時点では予想される結果は得られていない。

  競争的資金


• 前立腺癌におけるアンドロゲンレセプター共役因子の機能解析と臨床応用

  碓井 亞, 松原 昭郎, 安本 博晃, 亭島 淳

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 松原 昭郎;安本 博晃;亭島 淳, 2006年 - 2007年, 連携研究者

  1)アンドロゲン非依存性前立腺癌細胞株の樹立 アンドロゲン依存性前立腺癌細胞株LNCaPをアンドロゲン除去下で長期間培養することにより、アンドロゲン非存在下で増殖能を獲得した細胞株を得た。同株はMTTアッセイでの検討では抗アンドロゲン剤添加で増殖抑制が見られなかった。今後、本細胞株の特性についてアンドロゲンレセプターの発現、突然変異などについてさらに分析を進める予定である。尚、アンドロゲンレセプター共役因子の関与に関しては現時点で十分な結果が得られていない。 2)前立腺癌におけるRIZ1遺伝子のDNAメチル化解析 ヒストンメチルトランスフェラーゼの1つをコードするRetinoblastoma-interacting zing finger gene(RIZ1)のプロモーター領域のメチル化解析により、前立腺癌では約40%にメチル化を認め、予後不良因子の一つであるGleason Scoreの高い癌でより高率であった。ホルモン非依存性前立腺癌細胞PC3ではRIZ1の発現が消失しており、脱メチル化剤により発現が回復するこ

  競争的資金


• ホルモン不応性ヒト前立腺癌に対する新しい治療法の開発

  松原 昭郎, 亭島 淳, 三田 耕司, 石 光広, 長谷川 泰久

  文部科学省, 科学研究費助成事業(基盤研究(C)), 基盤研究(C), 亭島 淳;三田 耕司;石 光広;長谷川 泰久, 2005年 - 2006年, 連携研究者

  ホルモン不応性ヒト前立腺癌に対する新しい治療法としてFGFR2IIIbを用いた遺伝子治療の臨床応用を目的として、FGFR2IIIbの増殖抑制効果、副作用、放射線療法やタキサン系抗がん剤との併用効果およびその作用機構を中心に基礎的研究を行った。具体的にはホルモン不応性ヒト前立腺癌細胞株PC3細胞にFGFR2IIIbをstableに導入し、放射線およびドセタキセルとの併用効果を引き続き検討した。 その結果、コロニー形成試験では、FGFR2IIIb導入PC3は対象株に比較して外照射量依存性に有意なコロニー形成の低下を認めた.また0,4,8Gyの照射量を用いて抗アネキシン抗体陽性細胞の割合を経時的に検討したところ、FGFR2IIIb導入PC3細胆は対象株に比較して陽性率が高かった。また、APOPercentageによるアポトーシス実験においても同様にアポトーシス陽性細胞が増加した。このことから、FGFR2IIIbは外照射によるPC3細胞へのアポトーシス誘導を高めることが示唆され、FGFR2IIIbと放射線治療との併用が期待された。

  競争的資金


• 前立腺癌におけるTip60のアンドロゲン依存性および放射線感受性への関与

  亭島 淳

  文部科学省, 科学研究費助成事業(若手研究(B)), 若手研究(B), 広島大学, 2005年 - 2006年, 研究代表者

  1)前立腺癌におけるRIZ1遺伝子のDNAメチル化解析 前立腺癌、腎癌組織における免疫組織化学的検討により正常組織に比較して染色性の低下を認める分子群が同定され、癌組織における発現低下が示唆された。その発現低下のメカニズムを解明するため、各々の遺伝子について、メチル化特異的PCRを用いてDNAメチル化の解析を行った。その結果Rb蛋白の結合蛋白の一つをコードするRetinoblastoma-interacting zinc finger gene(RIZ1)について、前立腺癌組織の42.6%においてDNAのメチル化が認められた。RIZ1におけるDNAメチル化の検出率はGleason score7以上の群では53.3%と、Gleason score6以下の群での23.5%に比較して高率であった。また、前立腺癌細胞株のうちPC3において、DNAメチル化による-RIZ1の発現消失と、脱メチル化剤添加による発現回復が確認された。これらの結果より、DNAメチル化によるRIZ1の発現低下が前立腺癌の発生や増殖に重要な役割を果たしている可能性が示唆された。 2)アンドロゲン非依存性前立腺癌

  競争的資金

• 特別講演．新時代における転移性腎細胞癌の治療 ～「役者たち」の出番について考える～

  講師, 2019年, 金沢, 学術団体


• 特別講演．腎細胞がんの治療 ～めまぐるしい変化の中で考えること～

  講師, 2019年, 静岡, 学術団体


• 特別講演．腎癌の治療 ～めまぐるしい移り変わりの中で～

  講師, 2019年, 弘前, 学術団体


• 特別講演．転移性腎細胞癌の治療 うつりゆく時代の中でのTKI

  講師, 2019年, 厚木, 学術団体


• 特別講演．悩みながらの転移性腎細胞癌治療～ふえた「役者たち」の最適な出番は？～

  講師, 2019年, 京都, 学術団体


• 特別講演．変わりゆく腎細胞癌の治療 ～「迷える1匹の子羊」として～．

  講師, 2019年, 高松, 学術団体


• 特別講演．新時代にも悩む転移性腎細胞癌治療 ～「役者たち」の最適な出番は？～．

  講師, 2019年, 徳島, 学術団体


• 特別講演．腎細胞癌の治療 ～とどまることを知らない変化と戸惑いの中で～．

  講師, 2019年, 名古屋, 学術団体


• 特別講演．前立腺がん外来診療を円滑にするために － 前立腺がん地域連携パスとホルモン療法における取り組みと課題

  講師, 2019年, 学術団体


• 特別講演．変わりゆく腎細胞癌の治療 ～「迷える1匹の子羊」として～

  講師, 2019年, 千葉, 学術団体


• 広島大学病院における泌尿器癌の治療 －最近の話題ー

  バイエル薬品(株)

  山口泌尿器科懇話会, 2012年11月 - 2012年11月, 民間企業


• 運営委員

  日本泌尿器科学会広島地方会

  日本泌尿器科学会広島地方会, 2012年06月 - 2012年10月, 非営利組織


• 広島大学における前立腺癌の治療

  広島県病院薬剤師会北支部・アステラス製薬株式会社

  第183回広島県病院薬剤師会北支部研修会, 2012年07月 - 2012年07月, 民間企業


• 広島大学病院および関連施設における腎癌治療の現状

  ノバルティスファーマ株式会社

  岩国RCC治療カンファレンス, 2012年05月 - 2012年05月, 民間企業


• 特別講演．めまぐるしい移り変わりの中で腎癌治療を考える

  講師, 秋田, 学術団体


• 特別講演．悩みながらの転移性腎細胞癌治療 ～ふえた「役者たち」の最適な出番は？～

  講師, 小山